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Surgical repair of torn tendons is a common orthopaedic procedure in the United 
States, with nearly 400,000 repairs occurring annually. Despite improvements in surgical 
techniques used to re-attach the tendon to its boney insertion, clinically successful 
outcomes amongst patients are variable and re-tear rates can be exceedingly high. The use 
of stem cells as an adjunct to surgical repair to aid in improving tendon healing and repair 
strength has gained much interest amongst the clinical community. Accordingly, many 
investigators have begun examining the ability of stem cells to differentiate into tenocytes 
using various methodologies including the application of growth factors and mechanical 
cues. We hypothesized that the differentiation of adipose derived stem cells (ADSCs) 
into tenocytes could be achieved via the application of soluble BMP-12, a growth factor 
believed to be involved in tenogenesis and which has exhibited the ability to induce neo-
tendon formation following ectopic delivery in rats. Furthermore, we believed that the 
application of cyclic tensile strain, in addition to the application of BMP-12, would 
enhance tenogenic differentiation. First, based on this hypothesis, we performed in vitro 
studies to determine the ideal differentiation conditions to obtain a tenocytes-like 
phenotype. Because there is no one specific marker for tenocytes, an array of markers 
was used to capture the profile of a tenocytes, which includes scleraxis, tenomodulin, 
collagen I and collagen III. Results showed increased tenocytes-like phenotype in ADSCs 
differentiated statically for 7 days on monolayer. Using these results, an animal study was 
performed on the Achilles tendon of male Lewis rats (n=60) to determine the effects of 
BMP-12 differentiated ADSCs on injured tendons. ADSCs were either differentiated 
 iii 
with BMP-12 or cultured in control medium at the optimal conditions and then seeded 
onto Conexa™ scaffolds for three days. At the three day mark, surgeons from the 
Steadman Hawkins Clinic of the Carolinas induced a window transection in the Achilles 
tendon approximately 2mm x 6 mm and mended the injury with a scaffold either seeded 
with no cells (n=20), undifferentiated ADSCs (n=20), or BMP-12 differentiated stem 
cells (n=20). The healthy, contralateral leg was used as a positive control. The animals 
were sacrificed at 7 weeks and the injured Achilles tendons were acquired for molecular 
(n=6), histological (n=4), and mechanical analysis (n=10). The same procedure and 
analyses were performed on the contralateral tendons. Results show that autologous cell-
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1. Literature Review 
1.1. Shoulder Anatomy 
 
The shoulder is comprised of two main bones, the humerus and the scapula, 
which come together at the humeral head of the humerus and the glenoid located on the 
end of the scapula, forming the glenohumeral joint. Articular cartilage, which is located 
on the humeral head, works to reduce the friction between these two bones, allowing it to 
act as a flexible ball-and-socket joint. The scapula also extends over the joint forming a 
roof-like structure called the acromion, which plays a role in tendon injury, as mentioned 
later. In order to help stabilize the humeral head within the glenohumeral joint, there is a 
small ring of fibrous cartilage, which surrounds the glenoid. This region is referred to as 
the labrum.  However, this region needs more support in order to sustain elevation of the 
arm, as well as rotation of the arm, which is achieved by four muscles and their tendon 
insertions into the humeral head called the rotator cuff. The rotator cuff is comprised of 
the supraspinatus muscle and tendon, infraspinatus muscle and tendon, subscapularis 
muscle and tendon, and the teres minor muscle and tendon, which can be seen in Figure 




Figure 1.1. A) Anatomy of the rotator cuff (posterior view): a) supraspinatus tendon, b) 
infraspinatus tendon, c) teres minor tendon, d) greater tuberosity, e) acromion, f) 
infraspinatus muscle, and g) teres minor muscle. B) Anatomy of the rotator cuff (anterior 
view): a) supraspinatus tendon, b) subscapularis tendon, c) long head of biceps brachii 
tendon, d) long head of biceps brachii tendon sheath, e) greater tuberosity of the 
humerus, f) acromion, g) coracoid, h) supraspinatus muscle, and i) subscapularis muscle 
 
These muscles attach onto the scapula and extend around the joint to insert into 
the humeral head, providing stability to the joint. Prior to insertion, however, these 




Figure 1.2. Fusion of the rotator cuff tendons prior to insertion into the humeral head. 
SC= Subscapularis, SP = Supraspinatus, IS = Infraspinatus, TM = Teres Minor. 
 
Each muscle of the rotator cuff is responsible for a specific function within this 
region. The supraspinatus originates on the Supraspinatus Fossa of the scapula and inserts 
into the greater tuberosity of the humerus, allowing it to help adduct the humerus and 
stabilize the head of the humerus within the glenohumeral joint, or glenoid cavity. 
Secondly is the infraspinatus tendon, which originates on the Infraspinatus Fossa of 
scapula and inserts onto the greater tuberosity of the humerus, allowing it to help laterally 
rotate, adduct and extend the shoulder joint, in addition to help stabilize the humeral head 
within the glenohumeral joint. Thirdly is the teres minor, which originate from the 
superior half of the lateral border of the scapula, but also inserts in the same region as the 
infraspinatus, providing the same functions. Lastly is the subscapularis, which originates 
on the subscapular fossa of the shoulder and insert into the lesser tuberosity of the 
humeral head. This placement around the rotator cuff allows for medial rotation of the 
shoulder joint and stabilization of the humerus in the joint [2]. 
 
 4 
1.2. Tendon Anatomy 
 
Despite the complex structure of the rotator cuff working to support the humerus 
and protect the surrounding regions from damage, primary disorders in and around 
tendons arising from overuse, generically termed tendinopathies, and are responsible for 
a large portion of morbidity among individuals today. Tendons are a specialized form of 
fibrous connective tissue within a body that are organized to resist tensile forces. Their 
three main roles within the body are to stabilize the joint, to transmit mechanical forces 
from skeletal muscle to bone, and to act as shock absorbers to limit muscle damage [3]. 
Tendons can be found in a variety of forms, including rounded cords, strap-like bands, or 
flattened ribbons, and when healthy, appear intensely white. Structurally, they are 
composed of primary (fibers), secondary (fascicles), and tertiary collagen fibril bundles 
wrapped in endotenon, as shown in Figure 1.3 [4]. In order for these fibrils to form, 
soluble tropocollagen molecules must cross-link the insoluble collagen molecules. These 
bundles are in turn wrapped in epitenon, forming the actual tendon, and again in 
paratenon in most cases [4]. The paratenon is a layer of thin tissue composed of both 
collagen I and III, and an inner lining of fluid rich in mucopolysaccharides that provide 
lubrication, prevent friction, and protect the tendon [5]. 
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Figure 1.3. Biological structure of a healthy tendon. 
 
The cellular composition of tendons is approximately 90-95% tenoblasts and 
tenocytes, and 5-10% chondrocytes at the bone attachment and insertion sites, synovial 
cells found within the tendon sheath, and lastly, vascular cells, such as capillary 
endothelial cells and arteriole smooth muscle cells found passing through the endotenon 
and epitenon (5-10%) [4,6].  Tenoblasts are immature tenocytes. As tenoblasts age into 
tenocytes, their morphology changes from spindle-shaped containing multiple 
cytoplasmic organelles to condone their high metabolic activity, into more elongated cells 
characterized by a lower nucleus-to-cytoplasm ratio with decreased metabolic activity. 
Oxygen consumption in tendons, compared to skeletal muscle, is 7.5 times lower [7]. 
Due to a low metabolic rate, tendons undergo slow healing after injury [8]. Not only are 
tenocytes in control of energy generation, they also synthesize collagen and the entire 
extracellular matrix (EMC). The ECM is composed of proteoglycans, such as decorin, 
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versican, and lumican, glycosaminoglycan (GAG), glycoproteins, such as tenascin and 
elastin, and other small molecules [9]. The tenocytes and tenoblasts position themselves 
longitudinally between the collagen fibres [8].  The structural composition of the 
extracellular matrix of tendon includes collagen, predominately type I, but also small 
amount of II, III, IV and V, which accounts for 65-80% of tendons dry weight, and 
elastin, approximately 2% of the dry weight. However, the dry weight only comprises 
30% of the total tendon mass, with water within the ground substance accounting for the 
remaining 70%. These substances allow tendons to possess their characteristic 
mechanical properties, with collagen type I providing tendons the ability to withstand 
high loads and elastin providing the flexibility and elastic properties. 
 
1.3. Tendon disorders 
 
Tendon disorders are a large portion of the cases rheumatologists and orthopaedic 
surgeons deal with on a day-to-day basis, especially in the ageing, sedentary population. 
Such injuries also prove to be disabling for several months even with appropriate 
management [10]. On average, lesion presence in cadavers is equal to 80% in specimens 
of patients over 80 years, 50% in specimens of patients over 70 years, 30% in specimens 
of patients over 60 years, and 6% in specimens from cadavers of patients aged less than 
60 years [11].  This is partially due to the decrease in tendon blood flow and changes in 
proteoglycan and collagen composition within the tendon that occurs with increased 
aging [12]. Because tendons disorders are so prevalent, over 400,000 rotator cuff repair 
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surgeries occur annually in the United States alone [13].  
 
 Injuries within a tendon can be classified as acute, such as tendon rupture, or 
chronic, and are caused by either intrinsic or extrinsic factors, or a combination of the 
two. Intrinsic factors are more pathological and many studies have been done to observe 
these effects. Holmes and Lin observed the effects of multiple endocrine-metabolic 
diseases, such as diabetes mellitus, obesity, and hypertension, among others, on tendons 
[14]. Diabetes mellitus was found to have a positive correlation with the development of 
tendinopathy in men younger than 44, hypertension was associated with tendinopathy in 
women, and obesity had a positive correlation within males and females. For example, 
elevated glucose levels results in the accumulation of advanced glycation end products 
(AGEs) in tendon tissue, causing the tendons to become stiffer, despite their ability to 
withstand an increase in load and tensile stress compared to non-glycated tendons 
[15,16]. High amounts of AGEs also cause collagen fibrils to fuse together, resulting in 
an increased diameter. Lastly, connective tissue growth factor in fibroblasts is also up-
regulated by the presences of AGEs, promoting the formation of fibrosis in diabetic 
patients over time [17,18,19]. Extrinsic factors are classified more commonly as overuse 
injuries or fatigue, such as excessive distance while running or erroneous running 
technique [20]. During vigorous physical training, excessive loading of tendons has been 
shown to be the main pathological stimulus for tendon degeneration.  In the presence of 
intrinsic factors, tendinopathy development is more likely to occur due to excessive 
loading. Tendons respond to repetitive loading that occurs beyond the physical threshold 
of the tendon by either degeneration of their body, inflammation of their sheath, or a 
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combination of both [21]. In general, extrinsic risk factors predominate in acute cases, 
however when chronic trauma occurs, intrinsic factors play more of a role [8]. Despite 
these findings, the etiology of tendinopathy is unclear, although many causes have been 
hypothesized. 
 Mechanisms such as impaired apoptosis, bone spurs within the acromion 
reducing the area for the supraspinatus (2), osteophytes (4), ischemic damage, hypoxia, 
oxidative stress, hyperthermia, inflammatory mediators, and matrix metalloproteinase 
imbalance [3], have all been associated with tendon degeneration [4]. However, a large 
emphasis is placed on inflammatory mediators and matrix metalloproteinases (MMPs) 
because excessive overuse of tenocytes has shown to elicit their expression in vitro, 
suggesting this may trigger an increase in the photolytic activity within the tendon. This 
is exacerbated by damage to tendon fibers because MMP output is mediated by strain on 
the tendon cells through the cytoskeleton, however when the tendon fibers are damaged, 
the cells are released from strain regulation and an increase in collagenase activity and 
matrix degradation occurs [6]. Degenerative tendinopathy is the most common 
histological finding in cases of spontaneous tendon rupture, a form of acute injury. In a 
study analyzing 891 spontaneous tendon ruptures, 97% or 865 specimens showed signs 
of degenerative changes, while only 34% or 149 of 445 specimens showed degenerative 
changes in the control [22]. Following an acute injury, the body tries to mend the region 
and this occurs in three overlapping phases, as described later. 
 Over the past 15 years, molecular pathology of tendinopathy is becoming more 
defined and increasing our understanding of the issue. Important features to mention are 
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that an increase of messenger RNA of collagen types I and III, fibronectin, tenascin C, 
aggrecan and biglycan, as well as type III collagen proteins, are found in the injured 
tendon matrix. Despite the increase in collagen type I expression, injured tendons contain 
a higher percentage of collagen type III compared to normal tendons which contain a 
higher percentage of collagen type I. In addition, ruptured tendons show increased levels 
of MMP1, MMP9, MMP19, MMP25, and tissue inhibitor of metalloproteinase 1 
(TIMP1), and decreased levels of expression of MMP3, MMP7, TIMP2, TIMP3, and 
TIMP4 [6].  
 Within the shoulder rotator cuff model, tendon tears are most prevalent in the 
supraspinatus tendon near its bony insertion onto the humeral tuberosity. This insertion is 
broad, continuous, interwoven, and multilayered [23]. As tears in the supraspinatus 
widen, they begin to cause tearing in the infraspinatus tendon as well because these two 
tendons fuse 1.5 cm proximal to their insertions, as previously mention and as shown in 
Figure 1.1 [24]. What is important to know anatomically about this insertion region is 
that it is composed of four transition zones. The first zone, or tendon proper, is composed 
primarily of type I collagen and small amounts of decorin. The second zone, or 
fibrocartilage, is composed of primarily types II and III collagen, with small amounts of 
type I, IX, and X collagen. The third zone, or mineralized fibrocartilage, consists of type 
II collagen, in addition to type X collagen and aggrecan. The fourth zone is bone, which 
contains a higher mineral content and large quantities of type I collagen. In order for this 
attachment region to possess its unique properties, it must contain this gradient of mineral 
content and collagen fibre orientation that allows the tendon to withstand both tensile and 
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compressive forces [24]. However, when injury occurs, type III collagen percentages 
increase and despite the fact that collagen type III is present in normal tendons 
throughout the endotendon and epitendon, it can have detrimental effects when it 
becomes intercalated with collagen type I fibrils at the insertion sites of highly stressed 
tendons, like the supraspinatus. This is mainly due to the fact that collagen type III fibrils 
are smaller and less organized, which ultimately affects the mechanical strength of the 
tendon [6].  
 
1.4. Tendon Healing 
 
When injury to the tendon occurs, the body tries to repair the damage through the 
three phases of healing. The first phase consists of the inflammatory response, which is 
characterized by hematoma formation, fibrin deposition, inflammatory cells, fibroblasts, 
and the beginning of elastin and collagen fibrillogenesis. The second phase is 
proliferation, which is characterized by angiogenesis and fibroblast proliferation with 
collagen fibers displayed in random arrangement. Lastly, remodeling beings to restore 
normal vascularization, tendon crimping, collagen and elastic fiber orientation [25]. 
However, the overall structure, composition, and organization of the unmineralized 
fibrocartilage to mineralized fibrocartilage are not reestablished. This may be due to a 
variety of reasons, including inflammatory cells present at the tendon-bone interface, 
which precipitates scar formation in the region, or a potential lack of undifferentiated 
stem cells present in the healing region [26].  If a tendon were to rupture, surgical repair 
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would be necessary to promote healing. Despite these processes, the biomechanical and 
the biochemical properties of healed tendon never match those of intact tendon [4].  
Bruns et. al. have shown that after 12 months of spontaneous healing, transected sheep 
Achilles tendon had a rupture force only 56.7% of the normal rupture force [27]. In 
addition, failed healing or recurrent tears of the rotator cuff after repair of large or 
massive tears is a major complication, with structure failure rates acknowledged to be 
13% to 94% [26].  In order to enhance tendon healing to bone, a graft is needed to bridge 
the injury site during surgical repair. This provides three possibilities: 1) Allografts, 2) 
Autografts, and 3) Xenografts. However, each of these options is not ideal, typically. If 
rotator cuff disease is present, causing the initial tendon tear, then it is highly likely that 
the other tendons within the cuff are also diseased. Therefore, an allograft would not be 
ideal because the new graft would not be strong mechanically in comparison to a healthy 
tendon. Therefore, the autograph has a high potential to rupture than a healthy tendon. 
Secondly are autografts, however if foreign cell markers are not removed appropriately, 
they can cause an immune response and undergo rejection from the host. Lastly are 
xenografts, but the FDA has not approved them for use in tendons. Tissue-engineering 
studies, however, have shown that the insertion of stem cells into a repair region appear 
to be not only safe, but when introduced in conjunction with a scaffold and growth 
factors, actually enhances rotator cuff healing [28,29,30]. Improvement in the rotator cuff 
due to stem cells is thought to be because stem cells have a high intrinsic capacity for 
regeneration, which tendon cells, or tenocytes, do not possess. Therefore, the stem cells 
can produce tissue that is similar to the pre-injured tissue, however these results are 
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variable depending on the treatment [31].  
The use of stem cells to enhance tendon healing is being explored more everyday. 
There are three main types of stem cells within the body used for tendon repairs, which 
include bone marrow derived stem cells (BMSCs), originating in the bone marrow, 
embryonic stem cells (ESCs), residing within an embryo, and lastly, Mesenchymal stem 
cells (MSCs) which can be obtained from adipose tissue. Multiple studies have been 
performed to observe their effects on tendon healing. In a study done on 141 racehorses 
that obtained an overstrain injury in their flexor tendons, it was found that the injection of 
MSCs into the region significantly reduced the re-injury rate in the tendon two years after 
surgery [32]. In another study dealing with tendon defects in the rat tendon, it was seen 
that the introduction of BM-MSCs tagged with BMP-12 actually increased cell-number 
elongation and alignment along the tensile axis. Greater matrix deposition was also seen, 
in addition to elevated expression of tendon markers [33]. Despite the ability BMSCs and 
ESCs have to improve tendon healing, it is hard to obtain these cell types. Cell removal 
must be done through an invasive procedure. However, Mesenchymal adipose derived 
stem cells have been shown to not only possess an extensive capacity to proliferate, but to 
also differentiate into multiple lineages. According to a study done by Zuk, these cells 
were capable of differentiating into chondrocytes, osteocytes, and adipocytes [34]. 
 However, all multipotent stem cells have this ability to differentiate. What makes 
adipose derived Mesenchymal stem cells so unique is that they can be removed 
minimally invasively through lipectomy or liposuction. This method also provides large 
quantities of the stem cells, so cell proliferation is not necessarily needed after the cells 
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are acquired. Due to these cells’ ability to differentiate, and tenocytes limited intrinsic 
capacity to regenerate, researchers have been examining the effects of the addition of 
cytokines either into the region receiving stem cell therapy, or differentiating the stem 
cells using cytokines prior to their insertion into the tendon, to determine if improved 
healing is occurring. Because there is no one specific cell marker for tenocytes, an array 
of markers characteristic of tendons is used to analysis the healing of tendons through 
processes such as rt-PCR and Western Blot. Some of these markers include scleraxis, 
which is a transcription factor, tenomodulin, which is a type II transmembrane 
glycoprotein, and collagen I and III, which are connective tissue proteins [35]. Certain 
cytokines, which are used for differentiation are of specific interest to researchers due to 
their increased expression levels of tenocyte markers during the repair stage of healing. 
During this stage, fibroblasts become activated and begin excreting basic fibroblast 
growth factor (bFGF), insulin-like growth factor-1 (IGF-1), platelet derived growth 
factor-β (PDGF-β), vascular endothelial growth factor (VEGF), and bone morphogenic 
protein -12 (BMP-12), BMP-13, and BMP-14. PDGF-β has shown to enhance tendon 
healing due to the production of type I collagen level, however IGF-1 and bFGF have 
adverse effects on tendon healing. IGF-1 has been noted to exert an anabolic effect on 
tendon healing, despite its ability to increase collagen synthesis. bFGF increases the level 
of collagen III significantly more than collagen I, reducing the mechanical properties of 
the tendon [26].  Other studies have shown, nevertheless, that BMP-12 and TGF-β1 are 
both capable of differentiating Mesenchymal stem cells into a tenocyte-like phenotype. 
[33,36,37,38,39]. In addition, uniaxial dynamic loading placed on the cells for 2hr/day 
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during differentiation has shown to up-regulate scleraxis and collagen I expression, 
compared to cells cultures on monolayer [39]. It was hypothesized that these results were 
seen because the uniaxial loading stimulates tenoblast activities, such as fibroblast 
proliferation and collagen synthesis and alignment [40,41,42].  
 
1.5. Project Objective 
 
Therefore, because adipose derived Mesenchymal stem cells have a high capacity 
for proliferation and differentiation, and that they are easily accessible, I wanted to 
develop a scaffold seeded in autologous adipose derived stem cells differentiated into 
tenocytes that could be used to bridge the tendon injury site during repair to further 
improve tendon healing after repair. This would not only help reestablish a healthy 
tenocyte presence in the region where damaged tenocytes have a lower intrinsic capacity 
for regeneration, but it would also provide a large source of collagen I to mechanically re-
strengthen the tendon by reestablishing the collagen I:collagen III ratio found in healthy 
tendons. In order to do this, I had to first determine the ideal differentiation period, 
differentiation supplementation concentrations, and differentiation environment 
(mechanically and structurally). 
 
1.6. Animal models 
 
To test the healing effects of the scaffolds, they needed to be tested within an 
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animal model. Over the years animal models have contributed to our understanding of the 
physiology, pathology, and biomechanics of tendons. Due to the fact that I am more 
interested in seeing the healing effects of the scaffold in terms of tendon repair and not 
just the rotator cuff model, it provides a little more flexibility for choosing the animal 
model. However, as a comparison, I will explain some models used for rotator cuff 
repair. First, are the rat models, which were developed by Soslowsky et al. This model is 
considered to be most similar to the human when respect to the bony anatomy and 
physiology [43].  
As mentioned earlier, the acromion is a region of the clavicle that extends over the 
glenohumeral joint, creating a roof. This structure is also found in the rat model. The 
presence of this arch and the interaction it has with the supraspinatus tendon is similar to 
that in a human, making this a good model to study the healing mechanisms and 
regenerative strategies for acute tendon-to-bone repair [44,45,46,47]. In addition, rats are 
lost cost, easy to manage, and allow for a large sample size. 
  Restrictions of the rat model include the inability to use stand-of-care repair 
techniques similar to those used in the human rotator cuff due to the small size of the rat 
shoulder tendons. Also, the rat and other animal models, undergo healing of the rotator 
cuff injury and scar tissue formation in the absence of treatment, which hinders the 
discrimination spontaneous healing and healing as a result of manipulation. Spontaneous 
healing does not occur in the human rotator cuff.  
  Large animal models are also an option, which includes animals such as dogs, 
rabbits, and sheep. These animals are different compared to humans because the 
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acromion is either extremely reduced or nonexistent [48,49]. In addition, the soft tissue 
anatomy of the shoulder is different in large animal models compared to humans because 
the tendons are highly articular, extremely aligned, and not interdigitated. This lessens 
their ability to retain sutures, like soft-tissue found in humans. These models are not used 
frequently to study chronic rotator cuff repair because after 6 weeks, injured tendons 
begin to retract and the muscles in the region atrophy and stiffen [50] However, the main 
drawback of large animal models are that their tendons are prone to re-tear, making them 
less effecting when studying the treatment effects of biological supplements. These 
supplements ultimately work to instead influence star tissue formation in the gap between 
the bone and the retracted tendon. In addition, they require more money and space to 
maintain, and due to their size, may limit the sample sizes attainable.  
  Therefore, large animal models were ruled out and rats were chosen for the 
animal study. Because the size of the rotator cuff tendons in rats are so small, the Achilles 
tendon was used to examine the effects of implanted scaffold containing with no cells, 
undifferentiated adipose derived stem cells, or BMP-12 differentiated adipose derived 
stem cells. In addition to the accessibility of the Achilles tendon, it has also been used in 
many studies to examine the effects of tendon repair [51]. 
  Conexa decellularized dermis scaffold used was chosen based on its availability 
and FDA approval for use in tendons. However, there are many scaffolds available for 
purchase that are approved for use by the FDA for implantation into humans. Some 
categories of these include pericardial xenografts (OrthoADAPT), synthetic scaffolds 
(Lars® ligament, Polt-tape®, etc.) dermal allografts (Graftjacket and Allopatch), and 
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AIM 1: OPTIMIZING THE DIFFERENTIATION OF LEWIS RAT ADIPOSE 
DERIVED STEM CELLS TOWARDS A TENOCYTE-LIKE PHENOTYPE 
 
2. AIM 1 
2.1. Introduction 
2.1.1. Project Rational 
 
Soft tissue tears are a very common occurrence in the Unites States. Despite how 
common surgical repair of these regions is, healing of tendon to bone is highly 
unpredictable due. For example, clinical studies have shown in the rotator cuff 
radiographic failures at the repair region in any where from 30-95% of patients two years 
after surgery, depending on the size and chronicity of the tear, the presence of fatty 
infiltration, and general age and health status of the patient. This is not only the case for 
the rotator cuff, however. The highest incidences of failed healing occur in the 
supraspinatus tendon of the rotator cuff, Achilles tendon of the leg, Patella tendon of the 
knee, and the lateral and medial tendon in the elbow [1, 2, 3]. Due to this, a graft is 
needed to help reduce the instances of retear, providing three possibilities: autographs, 
allografts, and xenografts. For example, in the rotator cuff, autografts are not ideal 
because if rotator cuff disease is present in the cuff causing the initial tendon tear, then it 
is highly likely that the surrounding tendons are also diseased and you would not want to 
use them as a potential graft source. Secondly are allografts, however you run the risk of 
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rejection due to foreign cell markers. Lastly are xenografts, but the FDA has not 
approved their use in the rotator cuff.  Tissue engineering studies, however, have shown 
that the injection of stem cells into the region of repair in conjunction with growth factors 
and a scaffold enhances rotator cuff healing [4,5,6]. Because tendons have a limited 
intrinsic capacity for regeneration, I wanted to use the regenerative medicine approach to 
construct a scaffold seeded in autologous adipose derived stem cells differentiated into 
tenocytes, which could be implanted during surgical repair. The goal would be to further 
enhance healing after surgery and hopefully reduce surgical failure rates by helping 
replenish the damaged tenocytes and providing a source of collagen I to the region to 
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Recombinant Mouse GDF-7/BMP-12 (779-G7) was purchased from R&D Systems. 
Recombinant Human BMP-12/GDF-7 (4572-100) was purchased from BioVision. 
Recombinant Human TGF-β1 (100-21) was purchased from PeproTech. 10 µl protease 
inhibitor cocktail (P-8340), Oil Red-O stain (O0625), and Ascorbate-2-phosphate 
(A8960) were purchased from Sigma-Aldrich Corporation. Anti-Collagen I antibody 
(ab34710), Anti-Collagen III antibody (ab7778), and Anti-SCXA antibody diluted 
(ab58655) were purchased from Abcam. Tenomodulin antibody (sc-98875) was 
purchased from Santa Cruz Biotech, Incorporation. QuantiTect SYBR Green PCR Kit 
(204143), RNeasy Fibrous Tissue Mini Kit (74704), TURBO DNA-free™ Kit 
(AM1907M), RETROscript® First Strand Synthesis Kit (AM1720), and the Rotor-Gene 
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Q (9001863) were purchased from Qiagen. BioFlex–Collagen Type I coated 6-well plates 
(BF-3001C-Each) were purchased from FlexCell International Corporation. BCA protein 
kits (23225) were purchased from Pierce Biotech. BM Chemiluminescence Western 
Blotting Kit (Mouse/Rabbit) (11520789001) was purchased from Roche Applied Science. 
LIVE/DEAD® Viability/Cytotoxicity Assay Kit (L-3224) and Goat anti-Mouse IgG (110-
33) were purchased from Invitrogen. NanoDrop 2000 was purchased from 
ThermoScientific. Ready gels 4-15% Tris-Acl 50uL, 10 wells (161-115B) were purchase 
from Biorad. Alcian Blue (A3157) and Alizarin Res S 1% (s2007) were purchase from 
Poly Scientific. Fetal Bovine Serum Premium was purchased from Atlanta Biologicals 
(S11150). DMEM containing 1g/L glucose (MT-10-014-CM), 1X Phosphate Buffered 
Saline without Ca2+ and Mg+ (MT-20-031-CV), BSA from Rockland – fraction V 
(NC9418785), Dexamethasone (0.5g) (ICN19456190), β-glycerophosphate 
(ICN15724150), and Antibiotic/Antimycotic (MT-30-004-Cl) were purchased from 
Fisher Scientific. Collagenase type I was purchased from Worthington Biochemical 
Corporation (XOM12195 CLS1). Anti-Prolyl 4-Hydroxylase β clone primary antibody 
(MAB2073MI) and Bioseparations Centrifugal Filter Device Microcon YM-3 (42404) 
were purchased from Millipore. 0.5mM isobutyl-methylxanthine (100000-554), Insulin 







2.3.1. Animal Model: Lewis Rats 
 
Lewis rats were the ideal animal species for this project because they are 
syngeneic, or genetically identical, allowing cells harvested from one rat to be 
transplanted into another without rejection. This allows cells isolated in AIM 1 to be used 
for AIM 2. The Achilles tendon was chosen for the animal study in AIM 2 due to its 
accessibility and relatively larger size compared to the supraspinatus tendon of the rotator 
cuff. 
 
2.3.2. Reconstitution of BMP-12 and TGF- β1 
 
BMP-12 and TGF- β1 were reconstituted before use. Differentiated cells from 
Study 1 were cultured in 50ng/mL Recombinant Human BMP-12 (BioVision, 4572-100) 
reconstituted to a concentration of 0.1 mg/mL in water containing BSA (50µg BSA per 
1µg of protein). After Study 1, all studies used Recombinant Mouse GDF-7/BMP-12 
(R&D Systems, 779-G7) reconstituted at 100µg/mL in sterile 4mM HCL containing at 
least 0.1% human or bovine serum albumin. Recombinant Human TGF-β1 (PeproTech, 
100-21) was reconstituted at .5mg/mL in 10mM Citric Acid containing 0.1% BSA and 




2.3.3. Lewis rat tissue collection 
 
Shoulder tissue samples were collected from Lewis rats for cell culture and 
molecular analysis. All arms were first skinned to expose the tendons. Shoulder 
supraspinatus and infraspinatus tendon samples were excised from the muscle and bone, 
combined, and placed in either warm control media for tenocyte isolation, as described in 
Table 2.2, for a maximum of two hours, or in RNAlater for tRNA isolation until isolation 
could take place. The legs extracted for mechanical testing were stripped of the skin to 
expose the tendon and muscle, and then the entire leg was extracted from the body 
halfway up the muscle belly. The legs were then wrapped in gauze moistened with PBS 
and stored at -80°C for future testing. Inguinal adipose tissue was also collected from the 
adult rats and placed in warm control media for a maximum of two hours until the 
Adipose Derived Stem Cells could be isolated for cell culture and molecular analysis. 
 
2.3.4. Lewis rat tenocyte isolation 
 
Lewis Rat tenocytes were isolated from the supraspinatus and infraspinatus 
tendon using the protocol below. These cells were then combined for culture. 
 
1. Make solution: 
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a. Collagenase solution:  1% Bovine Serum Albumin (BSA) + 2mg /mL 
collagenase type I (Worthington XOM12195 CLS1- >280 U/mg) in 1X 
PBS. 
2. Tendon tissue was collected into a sterile collection vessel containing pre-warmed 
DMEM (1g glucose/liter) +10% FBS + 1% Ab/Am and subsequently transported 
to lab within two hours of harvest.  
3. In an aseptic cell culture hood, tendon tissue was rinsed once in 20mL of sterile 
1x PBS to remove excess blood. 
4. The connective tissue surrounding the tendon (peritenon sheath) was carefully 
removed with sterile scissors and tweezers. 
5. Tendon was minced into approximately 5 x 5 mm pieces/cubes with sterile scalpel 
blades in a sterile petri dish (95 x 15 mm). 
6. 20mL of sterile filtered collagenase type I (Worthington: 280U/mg) solution was 
added and incubated for 192 minutes at 37˚C in a humidified cell culture 
incubator at 37oC at 5% CO2 and were agitated every 5-10 minutes. 
7. Digests were then filtered through sterile 100µm mesh sieves into sterile 50mL 
conical tubes. 
8. Samples were then transferred to 15mL conical tubes (two per sample) for 
centrifugation (to obtain improved cell pelleting). 
9. Centrifuge at 1500 rpm for 10 minutes. 
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10. Supernatant was aspirated and cells were re-suspended in fresh media 
(DMEM+10% FBS+1% Ab/Am) and were subsequently centrifuged at 1000 rpm 
for 5 minutes to wash the cells. 
11. Cells were then re-suspended again and plated at a density of ~ 5000 cells/cm2 
into T-25 flasks. 
12. Undigested samples (sample caught in the mesh filter) were plated in a 6-well 
plate with only a drop or two of media to allow the cells to migrate out over time. 
 
Collagenase type I solution was sterile filtered before use. The tendons were kept 
in the collagenase solution for a total time of three hours and 12 minutes. The tenocytes 
were then cultured in expansion medium, as described below in Table 2.2. The 
undigested tendon samples were placed in a six well plate and allowed to culture until 
75% confluence was achieved. Isolated tenocytes were used as a positive control for later 
RNA studies. 
 
2.3.5. Lewis rat Adipose Derived Stem Cell isolation and culture 
 
Lewis rat Adipose Derived Stem Cells (ADSCs) were isolated from the inguinal 
fat pads excised from Lewis rats using the protocol below. Due to their ability to 
differentiate into multiple cell types, more specifically tendon cells, and the fact that this 
region is easily accessible and can be removed in a non-invasive, non-painful, and non-
terminal manner, it was chosen for isolation. 
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1. Make solutions: 
a. Collagenase solution:  1% Bovine Serum Albumin (BSA) + 2mg/mL 
collagenase type I (Worthington XOM12195  CLS1- >280 U/mg) in 1X 
PBS. 
b. NH4Cl Solution: 0.1mM EDTA + 155mM NH4Cl in 1X PBS. 
2. Inguinal adipose tissue collected from adult rats in DMEM (1g glucose/l) 
+10%FBS + 1% Ab/Am – collected fat from each rat in separate 15mL conical 
tubes filled with 5mL media. 
3. Cut adipose tissue into small pieces in a sterile petri dish with scalpel blades and 
put into 50mL conical tubes filled with 20mL collagenase (280 U/mg in 60mL to 
get 15,000 U total) solution. 
4. Incubate the samples for 2 hours at 37˚C under agitation. 
5. Shake every 5 to fifteen minutes. 
6. Filter samples through 100µm sieves into new 50mL conical tubes to dissociate 
any remaining connective tissue. 
7. Remaining fat was rinsed twice with control DMEM media (10%FBS +1% 
Ab/Am) through a 100µm sieve and then placed into a six well plate with only a 
drop of media to allow fat/cell adhesion. 
8. Transfer filtered collagenase containing cells to a new 15mL conical tube for 
centrifugation (to obtain improved cell pelleting). 
9. Centrifuge at 1000 rpm for 5 minutes. 
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10. Aspirate supernatant (leave ~2mL collagenase solution to avoid sucking up pellet) 
and re-suspend in 5mL NH4Cl solution for 5 minutes at room temperature. 
11. Centrifuge at 1000rpm for 10 minutes. 
12. Aspirate supernatant (leave ~ 1mL of solution again) and re-suspend in 3mL of 
control media (DMEM+10%FBS+1% Ab/Am) 
13. Count and plate cells at preferred cell density. 
 
The Collagenase type I solution was sterile filtered before use, as well as the 
NH4Cl solution. The fat globules were kept in collagenase solution for a total of two 
hours and the cells isolated were cultured in expansion medium, as described below in 
Table 2.2. The undigested fat globules were placed in a six well plate with minimal 
media until the tissue attached to the surface. Once attached, enough media was added to 
the well to cover the tissue. The media was changed every two days until the preferred 
confluence was achieved, at which point the cells were frozen down using the protocol 
below.  
 
2.3.6. Cell passaging, trypsinization, and freezing 
 
Once the isolated Lewis rat tenocytes and Adipose Derived Stem Cells had been 
cultured to the maximum confluence, they were either passaged or frozen down and 




Wash each T-150 flask with 20 mL of DPBS 1X – remove from flask. 
1. Repeat. 
2. Place 3mL trypsin in each flask and make sure it is spread out evenly over the 
cells. 
3. Place in incubator for 5 minutes. 
4. Tap the bottom of the flask to help cell removal and observe under the microscope 
after the 5-minute period. 
5. If all are detached, place 10mL of media into each flask. 
6. Move the media in each flask into individual 15mL conical tubes. 
7. Spin the conical tubes down at 1000 rpm for 5 minutes. 
8. Remove media except for 0.5mL. 
9. Re-suspend the cells in each conical tube individually. 
10. Consolidate the cells into a 50mL conical tube- or however many needed. 
11. If volume of media needs to be adjusted, you can spin the cells down again and 
re-suspend them in the appropriate media. 
12. Count the cells. 
13. Aliquot the appropriate amount of cells into new T-150s for expansion. 
 
CELL FREEZING 
NOTES & MATERIALS: 
1. Typically freeze down approximately 2x106 cells per mL in a cryovial 
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2. Freezing Media A: make in a sterile 15mL conical tube 
§ For every 1mL of freezing media A (make a total of 10mL): 
o 0.6mL MesenPro Complete Media 
o 0.4mL Fetal bovine serum 
3. Freezing Media B: make in a sterile 15mL conical tube 
§ For every 1mL of freezing media B (make a total of 10mL): 
o 0.8mL MesenPro Complete Media 
o 0.2mL Dimethylsulfoxide (DMSO) 
 
PROCEDURE: 
1. Rinse cells twice with 1x PBS (without calcium and magnesium), use 
approximately 15mL per T-150 flask. 
2. Add ~ 3mL of pre-warmed trypsin/EDTA solution to each T-150 culture 
flask and incubate for 5-7 minutes. 
3. Add ~ 10mL of pre-warmed MesenPro Complete media to trypsinized cells 
and transfer in sterile 15mL conical tubes. 
4. Spin down cells into a pellet at 1,000 RPM for 5 minutes. 
5. Remove all except 1mL of supernatant and then re-suspend cells by gentle 
pipetting. 
6. Combine all cells into one sterile 15mL conical tube. 
7. Count cells and determine the total volume of media needed to yield 4x106 
cells/mL. 
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8. Spin down cells, remove all media and re-suspend cells in Freezing Media A 
to a density of 4x106 cells/mL. 
9. Add an equivalent volume of Freezing Media B in a drop-wise fashion to 
yield a final cell density of 2x106 cells/mL.  Mix by gentle pipetting. 
10. Aliquot out 1mL of cell suspension into each cryovial. 
11. Seal cryovial and place in plastic freezing container and transfer to -80oC 
freezer for 24 hours. 
12. Following 24 hours at -80oC, transfer cells into liquid nitrogen tank. 
 
2.3.7. Gene Expression Analysis 
 
These protocols were used for all gene expression analyses in AIM 1 and AIM2. 
Gloves must be worn at all times when handling tRNA to prevent contamination of the 
sample.  
 
tRNA ISOLATION AND DNASE TURBO TREATMENT OF CELLS, SCAFFOLDS, 
AND TISSUE  
tRNA was isolated from cells, scaffolds, and tissue using the RNeasy Fibrous 
Tissue Mini Kit (Qiagen, 74704) with the protocol found below. For each study, three 
wells/scaffolds/extracted tissues were pooled to obtain an n= 2 samples. To prevent 
tRNA degradation, samples were placed on ice during isolation. It is important to remove 
contaminating DNA to prevent it from being amplified in the PCR reaction, which was 
done using the TURBO DNA-free™ Kit (Ambion, AM1907M). tRNA samples were 
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then stored at -80°C until RNA quantification could be performed using the protocol 
found below. 
 
FROM FRESH TISSUE/SCAFFOLDS AND TISSUE/SCAFFOLDS IN RNAlater: 
1. Remove scaffolds with cells from well plate using sterile forceps. Do not use 
more than 30 mg total weight of sample. 
2. Immediately place in liquid nitrogen to snap freeze. 
3. Pulverize quickly and add to sterile RNase free 2mL tube. 
4. Add 300µL RLT buffer to tube containing pulverized sample. 
5. Homogenize for 30 seconds. 
6. Add 590µL of RNase-free water to the lysate and then add 10µL of supplied 
proteinase K solution and mix thoroughly by pipetting. 
7. Incubate at 55oC for 10 minutes. 
8. Centrifuge at room temp for 3 minutes at 10,000xg. 
9. Pipette only the supernatant into a new 2mL microfuge tube. 
10. Add 450µL of 100% ethanol (RNA use only ethanol in flammable cabinet) and 
mix well by pipetting.  Do not centrifuge. 
11. Transfer 700µL of the sample, including any precipitate to an RNeasy mini spin 
column placed on a 2mL collection tube. 
12. Centrifuge at 10,000xg for 15 seconds at room temp.  Discard flow through. 
13. Repeat step 11 and 12 for the remainder of the sample. Poole three 
scaffolds/extracted tissues to obtain an n=2 samples. 
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14. Proceed to step 7A. 
 
FROM CELLS IN MONOLAYER CULTURE IN WELL PLATES: 
1. Wash wells three times with PBS (no Ca2+ or Mg2+) 
2. Proceed to step 1A below.  
 
FROM CELLS IN RNALATER: 
1. Transfer the cells in RNA later to a 50mL tube, and add 3x volume RLT w. β-
ME. 
2. Homogenize for 30 seconds. 
3. Add EtOH 70% and mix well by vortexing. 
4. Proceed to step 4A below. 
 
1A. Add 350µL of RLT buffer (with β-ME: 10µL β-ME per 1mL of RLT) to each 
well and scrape with cell scraper. 
2A. Transfer to an RNase free 2mL tube and homogenize by passing lysate through a 
20 G syringe at least 7 times. 
3A. Add 350µL of FRESH 70% EtOh to each tube containing homogenate.  Pipette 
thoroughly in order to mix well. 
4A. Add up to 700µL of homogenate to a spin column with attached 2mL collection 
tube. 
5A. Centrifuge at 10,000xg for 15 seconds. 
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6A. Repeat until entire volume is spun through column. (n=2 samples) 
7A. Discard flow through and re-use collection tube.  
8A. Add 700µL RW1 to column and centrifuge at 10,000xg for 15 seconds.  Discard 
flow through and re-use collection tube. 
9A. Add 500µL RPE buffer to column and centrifuge at 10,000xg for 15 seconds.  
Discard flow through and re-use collection tube. 
10A. Add 500µL RPE buffer to column and centrifuge at 10,000xg for 2 minutes. 
Discard flow through and collection tube. 
11A.  Place columns on new 2mL collection tube and centrifuge at max speed for 1 
minute. 
12A.  Place the spin column on a new 1.5mL RNase-free collection tube, add 40µL 
RNase-free water and centrifuge for 1 minute at greater than 10,000 RPM to 
elute the RNA. 
13A. Add another40µL RNase-free water to the column membrane and centrifuge for 
1 minute at greater than 10,000 RPM to elute the RNA.   
 
Place tubes on ice until they can be transported and stored in the -80oC or proceed 
to DNase Turbo treatment below to remove contaminating DNA. 
 
14A.  Add 8µL of 10X turbo DNase reaction buffer to the 80µL RNA sample and 
mix gently by pipetting (this yields a 1X buffer concentration – can adjust this 
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depending on your volume, however you always want a 1x buffer in your final 
volume). 
15A.  Add 1µL of DNase I reagent and mix gently by pipetting. 
16A.  Incubate for 30 minutes at 37 ºC. 
17A.  Add 8µL of DNase inactivation reagent and mix well by pipetting. 
18A. Incubate 5 minutes at RT with occasional mixing every 2 minutes by flicking 
the tube with your finger. 
19A.  Spin at 10,000 g (11,000 rpm) for 1 ½ minutes at 4 ºC, remove ~60µL 
supernatant (don’t want to suck up any of the DNA pellet). 
20A. Place 60µL into new RNase free 2mL microfuge tube and place on ice until 
samples can be transported and stored at -80oC. 
 
tRNA QUANTIFICATION USING THE BIOANALYZER CHIP 
For quantification, the chip priming station was cleaned, the electrodes were 
decontaminated, and the bioanalyzer was set up. The software used for quantification was 
the 2100 Expert Software. All tasks were performed according to the Agilent RNA 6000 
Nano Kit Guide [1]. While quantifying the samples, they were placed on ice to prevent 
degradation of the tRNA. 
 
EQUIPMENT:  
1. RNA 6000 Nano Assay Kit (Agilent Technologies, 5067-1511) with Agilent 
RNA 6000 Nano Chips and Nano Reagents (ladder, dye concentrate, marker, and 
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gel matrix) 
2. Chip Priming station   
3. IKA vortex mixer (Model MS2-S8/MS2-S9) 
4. 16-pin bayonet electrode cartridge 
5. PCR machine/heating block set to 70 0C   
6. RNAseZap (Ambion, Inc., 9780) 
7. RNase-free water 
8. Microcentrifuge  
9. Microcentrifuge tubes 
10. Pipette and tips   
11. Ice   
   
TRNA QUANTIFICATION USING THE NANODROP 2000 
tRNA concentration quantification was also performed using the NanoDrop 2000 
(ThermoScientific) and the protocol below. While quantifying the samples, they were 
placed on ice to prevent degradation of the tRNA. 
 
1. Using RNase free water, wash the sampled reader by placing 1µL on both the top 
and bottom platforms and dry with a KimWipe. 
2. Following the systems instructions, start the program and classify the samples 
being tested as “RNA” under settings. 
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3. Load 2µL of blank to the lower sensor and initialize the system by clicking 
“blank”. 
a. Blanks should be the same solution used to dilute tRNA samples in steps 
12A, 13A, and 20A during tRNA isolation. 
4. Dry the lower sensor and add 1µL of sample. 
5. Lower the arm and press “read”. 
6. After the sample has been read, record the data with the appropriate RNA 
concentration (ng/µl), A260/A280 and A260/A230 ratios. 
 
TRNA REVERSE TRANSCRIPTION WITH cDNA DENATURATION 
After the tRNA was quantified, it was reverse transcribed using the protocol 
below to create single stranded cDNA. Reverse transcription was performed using the 
RETROscript® First Strand Synthesis Kit (Ambion, AM1720) on the Rotor-Gene Q 
(Qiagen, 9001863). 
 
1. From the Agilent RNA chip, determine the volume of RNA required to yield 1 µg 
of RNA. 
2. Add 600ng -1µg RNA to a small PCR tube. FLICK THE TUBE, MAKE SURE 
IT’S MELTED. 
a. Should have to add no more than 10µL of RNA to the PCR tube to get 1 
µg total (however, if you have a low RNA yield you can use as little as 
400ng of RNA for reverse transcription). 
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3. Add 2µl of oligo dT (1st strand primer for reverse transcriptase – typically mRNA 
has poly-AAA tail, so oligo dT binds to it and acts as 1st strand primer) to the 
PCR tube containing the RNA. 
4. Add nuclease-free water to make a final volume of 12µL in the PCR tube. 
5. Mix gently, spin briefly and then heat PCR tube for 3 minutes at 70-85oC in the 
thermocycler (see below for more details on how to use the thermocycler). 
a. Heating gets rid of the RNA secondary structure that could impede reverse 
transcriptase from copying the RNA. 
6. Remove PCR tubes from heat and place on ice, spin briefly, and place back on 
ice. 
7. Add remaining RT components (should end up with 20µL final volume in PCR 
tube). KEEP ON ICE. 
a. 2µL – 10X RT buffer 
b. 4µL – dNTP mix (deoxynucleotide triphosphates- building blocks of the 
DNA) 
c. 1µL – Rnase inhibitor 
d. 1µL – Reverse Transcriptase (makes the cDNA from RNA) 
8. Mix gently using pipette at 10µl volume, spin briefly and then incubate at 42-
44oC for 1 hour in thermocycler. 
9. Incubate at 92oC for 10 minutes to inactivate Reverse Transcriptase 
10. Add an additional 20µl of DNase-free water to cDNA to yield a final volume of 
40ul. 
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11. Store resulting cDNA at -20oC or proceed to PCR. 
 
rt- POLYMERASE CHAIN REACTION (rt-PCR) 
Once the RNA was reverse transcribed into cDNA, the cDNA was amplified by 
real time Polymerase Chain Reaction using the QuantiTect SYBR Green PCR Kit 
(Qiagen, 204143) and the protocol below.  
 
1. Total the number of cDNA samples undergoing rt-PCR. 
2. Take the total and add one and then multiply it by each of the solutions below: 
a. 10µL of master mix 
b. 2µL forward primer 
c. 2µL reverse primer 
d. 4µL RNase free water 
3. For each gene of interest, combine the above reaction components together to 
create the master mix for that gene. 
4. Aliquot 18µL of each respective master mix into 0.5mL PCR tubes. 
5. Add 2µL of each respective cDNA template into each tube. 
6. Mix gently using pipette at 10µL volume and spin briefly. 
7. Place tubes into the RotorGene for 45 PCR cycles of the following: 
a. Hold at 95oC for 15 minutes. 
b. Cycle 
i. Denature: 94oC for 15 seconds 
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ii. Anneal: 50oC for 20 seconds 
iii. Extension: 72oC for 20 seconds 
c. Melt 72-99oC at 1oC per step first hold 30 seconds following hold 5 
seconds. 
 
The genes of interest for rt-PCR and their primer sequences, ordered from 
Integrated DNA Technologies, can be found below in Table 2.1. Before use, the primers 
were diluted from 25µM to a working solution of 5µM by adding 100µL of primer to 
400µL of RNase-free water. This was done for the forward and reverse primer for each 
gene. The annealing temperature in Step 7.ii. was chosen based on the lowest melting 
temperature among all the primers minus two degrees.  
 
Table 2.1: Primer Sequences used for RT-PCR 
     
# Primer Species Forward and Reverse Sequences Reference 
     
1 COLL-1 Rat F: TGGATGGCTGCACGAGT 
R: TTGGGATGGAGGGAGTTTA 
[2] 
2 COLL-3 Rat F: GCCTCCCAGAACATTACATAC 
R: CAATGTCATAGGGTGCGATA 
[2] 
3 Tenomodulin Rat F: CCAGACAAGCAAGCGAGGA 
R: AACTTCCTATTAGACTCTCC 
[3] 
4 Scleraxis Rat F: CTGGCCTCCAGCTACATTTC 
R: CCGTCTTTCTGTCACGGTCT 
[3] 







rt-PCR DATA AND STATISTICAL ANALYSIS 
2-ΔΔCt values were calculated for each sample that was underwent rt-PCR and 
normalized to the control group to determine whether there was an up regulation or down 
regulation of gene expression. Results were represented as a mean ± the standard 
deviation for each gene within a study group. All statistical analyses were performed for 
each gene of interest using a two-tailed t-test of unequal variance. Significant differences 
were signified by a p < 0.05. 
 
2.3.8. Histological analysis 
 
IMMUNOFLUORESCENCE 
Immunofluorescence for prolyl-4-hydroxylase will transmit red, while the DAPI 
will fluoresce the nuclei blue. 
 
1. Rinse cells in warm PBS. 
2. Fix cells with warm 4% formaldehyde or paraformaldehyde for 30 minutes. 
3. Permeabilize with triton for intracellular proteins / transcription factors. 
a. For intracellular proteins rinse 4X in PBS after fixing cells and then 
permeabilize with 0.2% triton for 5 minutes at room temp. Then rinse 
again 3-4X with PBS prior to blocking. 
4. Block with blocking solution (BS): 5% bovine serum albumin + 0.05% Triton for 
2 hours (can be left overnight) at 4oC. 
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5. Remove BS but do not rinse. 
6. Add primary antibody diluted according to manufacturers specifications in 
blocking solution and place at room temp for 2 hours (or overnight at 4oC). 
a. Recover primary antibody following incubation period. 
7. Rinse 3-4X with 1x PBS. 
8. Add secondary antibody (5µg /mL) diluted in BS for 1 hour at room temperature 
in the dark. 
9. Rinse 3-4X with 1x PBS. 
10. Add DAPI to cover the bottom of the well for 1-5 minutes. 
 
LIVE/DEAD IMAGING 




1. Sterile 1X DPBS 
2. LIVE/DEAD® Viability/Cytotoxicity Assay Kit (Invitrogen, L-3224) 
a. 4mM Calcein AM (component A) 
b. 2mM Ethidium homodimer-1 (component B) 
 
METHODS: 
1. Calculated the volumes of solutions needed to cover the samples per ratio below: 
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a. 1mL DPBS 
b. 0.5µL Calcein AM 
c. 2µL EthD-1 
2. Prepared the final solution: 
a. Added EthD-1 to DPBS then vortexed. 
b. Added Calcein AM to the solution above and vortexed. 
3. Aspirated all culture medium from the well. 
4. Rinsed the cells three times with warm DPBS. 
5. Added enough of dye solution to the well (approximately 0.5 to 1mL) to cover the 
scaffolds. 
6. Incubated at 37°C for 20 minutes in a dark place. 
7. Allowed the fluorescent lamp to warm for at least 15 minutes. 
8. Imaged using fluoresce filters to examine the cells. 
 




1. RIPA Buffer Recipe (for 100mL): 
2. 50mM Tris-HCl  0.788 g 
3. 150mM NaCl  0.876 g 
4. 1mM EDTA  37.2 mg 
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5. 1% Triton X-100  1.0mL 
6. 1% Sodium Deoxycholate 1.0 g 
7. 0.1% SDS   100 mg 
8. pH solution to 7.4 
a. Add 10 µl protease inhibitor cocktail (Sigma P-8340) per mL RIPA Buffer 
just before use 
 
PROCEDURE: 
1.  Rinse each well twice with 3mL of sterile PBS (without Calcium or magnesium). 
2. Add 500µL RIPA buffer containing protease inhibitor to each well. 
3. Use a rubber cell scraper (blue handle with white rubber windshield wiper looking 
thing on the end) and vigorously scrape the entire surface of the well. 
4. Transfer the solution in each well to 2mL centrifuge tubes using a 1mL pipette. 
Sonicate the material for 5 minutes, followed by 15 seconds of homogenization 
with metal tip in sterile 12 x 75 mm glass tube. 
a. Clean the tip before and after use in one change of 100% ethanol followed 
by one change of distilled water. 
5. Place on ice and let the solution cool for 20 minutes. 
6. Spin down the samples in the small centrifuge at 14,000 g for 15 minutes. 
7. Transfer supernatant (liquid on top) into two new 2 mL microfuge tubes and place 
in the -20C freezer until BCA performed. 
8. Solid pellet at the bottom of the tubes can be discarded. 
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BCA PROTEIN ASSAY 
Once the protein was isolated, the concentration was determined using a BCA 
Protein Assay Kit (Thermo Scientific Pierce, 23225). Diluted Albumin standards (BSA) 
was mixed according to the Pierce dilution scheme for standard test tube protocol and 
microplate procedure (working range = 20 – 20,000µg/mL) [5]. BCA working reagent 
was created and the microplate was prepared according to the Pierce instructions as well. 
After the 30-minute incubation in step 3, wells were allowed to cool for 5 minutes prior 
to wavelength reading. After BCA values were obtained, the value of the 562 nm 
measurement for the blank was subtracted from the 562nm measurement for the 
standards and unknowns. Using these values, a standard curve was plotted using the 
corrected standard 562nm measurements against the known concentration for each 
standard in µg/mL. This curve was used to determine the protein concentration of the 
unknowns. 
 
MICROCON CENTRIFUGAL FILTER DEVICE TO CONCENTRATE PROTEIN 
For samples that were not concentrated enough to obtain the desired concentration 
in 50µL of liquid, which is the maximum amount of liquid the well plate can hold, they 
were concentrated using the Bioseparations Centrifugal Filter Device Microcon YM-3 
(Millipore, 42404). First, the tubes were labeled and the samples were loaded into the 
filter reservoir (maximum 0.5 mL). After securing the tops, the height of the sample in 
the filter was marked. Samples were then spun at 14,000xg for 45 minutes and the height 
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of samples was checked. Ideally, a 5-10 fold increase in protein was wanted. Then, the 
sample reservoir was removed from the vial and inverted into a new clean vial. The vial 
was spun in the Microfuge for 3 minutes at 1,000xg to transfer concentrate to the vial. 
Three sample reservoirs for the sample study group were combined to obtain an n=2. 
Once completed, the samples were separated from the reservoir and stores at -20°C until 
BCA quantification was performed. 
 
SDS PAGE AND WESTERN BLOT 
Western blotting was performed using the protocol below to aid in determining 
protein concentrations among the study groups. For each western blot, 7µg of protein was 
desired in each lane during electrophoresis. 
 
MATERIALS: 
1. BM Chemiluminescence Western Blotting Kit (Mouse/Rabbit) (Roche Applied 
Science, 11520789001) 
2. Ready gels 4-15% Tris-Acl 50uL, 10 wells (Biorad, 161-115B) 
 
SDS PAGE/ELECTROPHORESIS: 
1. Sample preparation: 
a. Add appropriate amount of protein (to get 7µg) and sample buffer (to get a 
total of 40µL) into a 50µL tube (want a 1:1 ratio of protein to sample 
buffer so base concentration of sample buffer on how much is needed). 
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b. Add 4µL B-mercapthoethanol to each sample. 
c. Boil each sample for 5 minutes to break disulfide bonds. 
2. Make 2X Tris/glycine/SDS migration buffer (~500 mL per electrophoresis unit). 
a. 50 mL of 10X Tris/glycine/SDS buffer + 450 mL dH2O 
3. Insert gels with the comb (ridges) on the inside. 
4. Close clip simultaneously. 
5. Fill middle between gels with migration buffer until its half way between the top 
of the comb and the top of the plastic holding the gel. 
6. Check for leaks. If there are none, add the remaining migration buffer to the edges 
of the gels. 
7. Remove combs from the gels (use fingernails in the ridges) 
8. Load a max of 40µL of unknown samples in each lane and 15µL of MW standard. 
9. Run gel at 90V for 100 minutes while on ice. 
 
SOLUTIONS: 
1. TB–Transfer Buffer : 6.06g Tris, 28.8g Gly, 200 mL MetOH – fill to 2L with 
dH2O 
2. Tris 50mM (12.1g), NaCl 150mM (17.52g), - 2L with dH2O, pH 7.5 
3. Tris – Tween : 1 mL Tween20 in 1 liter Tris buffer  





A. Preparing PVDF membranes:(1 per gel) (start preparing 30-45 minutes prior to the 
end of the electrophoresis run) 
1. Cut out PVDF (polyvinylidine fluoride) membrane using sizing jig (in bottom of 
membrane box). 
a. Do not touch membrane; only use the tweezers at the corner once it is 
removed from between the two blue sheets.  Cut bottom left corner of 
membrane for orientation. 
2. Place membrane in 100% methanol for 20 seconds, then place in H2O for 2 
minutes (make sure the membrane is remains submerged here because it has a 
tendency to float), finally place membranes in transfer buffer for at least 5 
minutes. 
3. When electrophoresis gels are done running, remove from electrophoresis module 
and pry off the glass plate covering the gel.  Remove the top gel / fringes.  Place 
each gel in its own container containing transfer buffer.  Allow the gels to 
equilibrate to room temperature for 15 minutes. 
4. During equilibration time, wash the electrode holder box/bath to remove SDS, 
this needs to be clean so that we can use this module with the transfer cell. 
5. After equilibration of gels in transfer buffer, we are ready to make the gel 
sandwich for transferring the protein to the PVDF membrane.  Be sure to pre-soak 
components including fiber and filter pads in transfer buffer in two glass pyrex 
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pans.  Will build gel sandwiches in one pyrex pan while the other is used for pre-
soaking the sandwich components. 
6. Stack gel sandwich as follows: 
 Gel sandwich: avoid air bubbles! 
  Top:    
   --------------- clear side of the cassette (with handle) 
   --------------- pre-wetted fiber pad 
   --------------- pre- wetted filter paper 
   --------------- PVDF membrane 
   --------------- gel  
   --------------- pre-wetted filter paper 
   --------------- pre-wetted fiber pad 
   --------------- black side of the cassette 
  Bottom 
7. Once stacking is complete, roll a glass pipette over the top fiber pad to remove 
any air bubbles prior to closing the cassette. 
8. Place black side of cassette facing the black side of the transfer cell (red and 
black). 
9. Place transfer cell into clean electrophoresis module that contains a small stir bar 
in the center and fill with transfer buffer. 
a. Transfer cell: Electrode module, ice pack, 1-inch stir bar, TB → all in a 
ice bucket full ice 
10. Run electrophoresis module for 75 minutes at 100 V, make sure to surround 
module with ice and water. 
 
B. Processing of PVDF membranes – Equilibrate all solutions at RT 
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11. Before blocking carefully remove the membrane from the sandwich.  Mark the 
side facing the gel with a “J” or something to distinguish it and cut the bottom 
corner below the last MW marker. 
12. Block blots in 100 mL 2% NFDM (50mL/blot), at least 1 hour (shaking) –did 1.5 
hours 
13. Incubate the membrane over night at 4 o C without shaking in 1o Ab in 0.5% 
NFDM.  Allow equilibrating to RT before washing.  
14. Wash: 3X 15 min. in 100 mL Tris-Tween while shaking 
15. Change containers and wash 2X 12 min in 50 mL 0.5% NFDM in Tris while 
shaking. 
16. Incubate the membrane for 45-90 minutes with shaking in 2 o Ab (3.6µL in 60mL 
1% NFDM for anti mouse/rabbit kit) (30mL/blot) 
17. Wash : 4X 15 min. in 100 mL Tris – Tween. 
18. Transfer to a new container with Tris buffer. 
19. During the wash: 
a. Prepare detection solution: 250µL B (starting solution) + 25 mL A 
(substrate solution). Wrap in tinfoil until used in order to keep dark. 
20. Image 
 
WESTERN BLOT ANALYSIS 
To determine the relative density units (RDU) for each membrane, ImageJ 
software was used. Each lane of the membrane containing a sample was selected using a 
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uniformly sized box. The light density within the box was then measured and graphed to 
determine the peak density.  
 
2.3.10. Decellularized porcine pericardium preparation 
 
Porcine pericardium was used as a scaffold for cell seeding medium as described 
later. Prior to use, the pericardium was decellularized by lab member Mike Jaeggli. 
 
1. Punch out non-sterile decellularized pericardium using a 12 mm biopsy punch. 
2. Sterilize for 2 hours in 0.1% peracetic acid made in PBS, pH to 7.4. 
3. Place pericardial punches in peracetic acid in P cup and put on orbital shaker for 2 
hours and 35 minutes. 
4. Rinse thoroughly in 4 changes of sterile PBS, rinse for 15 minutes each change. 
5. Following rinsing, incubate sterile pericardial punches in sterile solution of 50% 
FBS, 1% Ab/Am, and 50% DMEM (1g/L glucose) for two hours, prior to cell 
seeding. 
 
2.3.11. Confirmation of Adipose Derived Stem Cell multilineage differentiation 
capability 
 
To validate the multipotency, or stemness, of the isolated Lewis rat Adipose 
Derived stem cells at passage 4, the cells were cultured in chondrogenic, adipogenic, and 
osteogenic medias, as detailed in Table 2.2, to induce differentiation. The listed medias 
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have shown to induce Chondrogenesis, Adipogenesis, and Osteogenesis, respectively, in 
Mesenchymal Stem Cells [6, 7]. For each group, cells were cultured in a total of six wells 
containing 2mL of their respective differentiation media at the appropriate density listed 
below. Media was exchanged in the wells every three days. Analysis was performed after 
the differentiation period using histological stains, as described in Table 2.3, to confirm 
multilineage differentiation. Each stain was passed through a 0.4µm filter beforehand to 




The LRAD stem cells were placed in a micromass and cultured to induce 
chondrogenic differentiation [6,8]. Each cell micromass was suspended in 10µL of the 
control media, as listed in Table 2.2, at a density of 8 x 106 cells/mL in the center of each 
Table 2.2: Medium Supplementation for Induced Lineage-Specific Differentiation of 
LRAD Stem Cells  
    
Differentiation 
Medium Basal Medium Serum Supplementation 
    
Control DMEM (1g/L Glucose) 10% FBS 1% antibiotic/antimycotic  
Chondrogenic 
(CM) 






DMEM (1g/L Glucose) 10% FBS 0.5mM isobutyl-methylxanthine 
(IBMX), 200µM 
indomethacin, 10µM insulin, 









well. The cells were allowed to attach for 2 hours at 37°C, followed by the gentle 
addition of chondrogenic media (CM) as to not disturb the cell pellet. 
Chondrogenesis confirmation analysis was performed after cells were cultured in 
CM for a total of 27 days using Alcian Blue (Poly Scientific, K066) histological stain at 
an acidic pH of 0.81.  Prior to staining, the cells were rinsed three times with sterile 
phosphate buffered saline (PBS) to remove the media, then fixed in 4% 
paraformaldehyde for 30 minutes at room temperature, and subsequently rinsed three 
times with distilled water (dH2O) to remove any residual chemicals. Due to the fact that 
previous studies have shown staining capabilities of sulfated glycosaminoglycan’s, which 
are present in cartilaginous matrices, by 1% (wt/vol) Alcian Blue in 0.1 N HCl (pH levels 
of 1 and below), the cells were then submerged in 3 mL of Alcian Blue 1% in 3% Acetic 
Acid pH 0.81 for 30 minutes at room temperature [6]. The cells were then rinsed with 
dH2O to remove excess stain and the cells remained submerged in it until imaging. 
 
ADIPOGENESIS 
A total of 1x106 Lewis rat Adipose Derived Stem Cells were seeded into each of 
the six wells of a six well plate and adipogenic differentiation of the stem cells was 
induced by culturing with AM, as described in Table 2.2, for a total of 28 days. The cells 
were then rinsed three times with PBS to remove residual media and fixed for 60 minutes 
with 4% paraformaldehyde at room temperature.  Next, the cells were rinsed twice with 
distilled water, followed by one quick rinse of 60% isopropanol and then a five-minute 
rinse with 60% isopropanol. To examine for intracellular lipid-filled vacuoles, as 
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described in Table 2.3, the cells were then stained at room temperature for 60 minutes in 
5% Oil Red-O working solution made in 99% isopropanol that was stirred overnight and 
filtered through a 0.4µm media filter [6]. The stain was then removed with one rinse of 
60% isopropanol and three subsequent rinses of distilled water. The cells were 
counterstained for one minute with Hematoxylin and rinsed until the distilled water was 
clear. The cells were immediately imaged. 
 
OSTEOGENESIS  
Lewis rat Adipose Derived Stem Cells were cultured with Osteogenic media, as 
detailed in Table 2.2, to induce osteogenic differentiation. Each of the six wells were 
seeded with 100,000 cells and allowed to differentiate for a total of 27 days. Cells were 
then rinsed three times with 3mL PBS in each well to remove the excess media and fixed 
for 30 minutes at room temperature using 4% paraformaldehyde. The cells were then 
rinsed with dH2O three times to remove any residual chemicals and stained with 3mL 1% 
Alizarin Red S working solution (PHG) (pH 6.00), as described in Table 2.3, for two 
minutes at room temperature to examine extracellular matrix calcium deposition. After, 
the cells were rinsed four times with distilled water to remove excess stain and remained 












2.3.12. Differentiation studies 
 
In order to differentiate the Lewis rat Adipose Derived Stem Cells into tenocytes, 
the cells were seeded into six well plates. Depending on the study group, the cells were 
either exposed to medium containing 50ng/mL BMP-12, 10ng/mL Recombinant Human 
TGF-β1 (PeproTech, 100-21), a combination of the two, or DMEM control media. Each 
medium contained 1% Ab/Am, along with varying levels of FBS depending on the study, 
which can be seen below in Table 2.4. Subsequently, the cells were placed in either a 
static condition or a dynamic condition where the cells were undergoing biaxial tension 
(FlexCell Int.) to determine whether a particular condition enhanced differentiation. 
 
Table 2.3: Histological Staining to Confirm Induced Lineage-Specific Differentiation of 
LRAD Stem Cells 
      
Lineage Histological Stain Working Solution 
Lineage-Specific 
Determinant 
    





Adipogenic Oil Red-O 
stain 
 
1. 0.5gms of Oil Red-O powder 
added into 100mL of isopropanol 
(aq) and mixed overnight 
2. Add 6mL of stock from above 





Stock Cell nuclei 
Osteogenic  Alizarin Red  
 
10mL of Ammonium Hydroxide 
0.1% (aq) added to 100mL of 






Table 2.4: Lewis Rat Adipose Derived Stem Cell Medium Supplementation for 
Differentiation Studies 
     
Study Group Basal Medium* Serum Supplementation 
     
Pre-
study 

















Control DMEM/F12 2% FBS 1% antibiotic/antimycotic 
1X ITS 
BMP-12 DMEM/F12 2% FBS 1% antibiotic/antimycotic 
1X ITS 
50ng/mL BMP-12 
Study 3  
Control DMEM 10% FBS 1% antibiotic/antimycotic 
BMP-12 DMEM 10% FBS 1% antibiotic/antimycotic 
50ng/mL BMP-12 
TGF-β1 DMEM 10% FBS 1% antibiotic/antimycotic 
10ng/mL TGF-β1 
BMP-12 +  
TGF-β1 




Control DMEM 10% FBS 1% antibiotic/antimycotic 
BMP-12 DMEM 10% FBS 1% antibiotic/antimycotic 
50ng/mL BMP-12 
TGF-β1 DMEM 10% FBS 1% antibiotic/antimycotic 
10ng/mL TGF-β1 
Study 5 
Control DMEM 10% FBS 1% antibiotic/antimycotic 
BMP-12 DMEM 10% FBS 1% antibiotic/antimycotic 
50ng/mL BMP-12 
*All basal medium contained 1g/L Glucose 
**ITS composed of 500ng/mL insulin, 500ng/mL transferrin, and 500ng/mL selenium 
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STUDY 1: DETERMINING THE IDEAL MECHANICAL DIFFERENTIATION 
CONDITION: DYNAMIC LOADING VS STATIC 
The first study focused on gene expression and histology of differentiated Lewis 
rat Adipose Derived Stem Cells at passage 3. Cells were expanded in MesenPro 
Complete medium and either cultured on BioFlex–Collagen Type I coated 6-well plates 
(FlexCell International Corp., BF-3001C-Each) or on monolayer for 8 days. All cells 
were seeded in their respective 6-well surface type and placed into the 37°C incubator for 
24 hours beforehand to ensure cell attachment prior to a seven day static or dynamic 
period. A seeding density of 500,000 cells per well was used in wells being analyzed for 
gene expression (n=3 wells), whereas a seeding density of 100,000 cells per well was 
used in wells being evaluated for histological analysis (n=3 wells).  There were a total of 
three groups for this study: dynamic surface with medium containing BMP-12 (n=6 
wells), dynamic surface with control medium not containing BMP-12 (n=6 wells), and 
static surface with medium containing BMP-12 (n=6 wells). The dynamic regimen can be 
found below in Table 2.5. 
 
Table 2.5: Regimen for Dynamic Testing 
    
Day Min Tension % Max Tension % Duration (hours) 
    
1 0 2.5 6 
2 0 5 6 
3 0 7.5 6 
4 0 7.5 6 
5 0 7.5 6 
6 0 7.5 6 
7 0 7.5 6 
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As shown in Table 2.4, each medium was made with DMEM/F12 (1g/L glucose), 
and additionally, contained only 2% FBS, and 1x ITS (500ng/mL Insulin, 500ng/mL 
Transferrin, 500mg/mL Selenium).  At the end of the 8th day, immunofluorescence (IF) 
was performed for histological analysis to determine the presence and abundance of 
Prolyl-4-hydroxylase within the static group according to the protocol above. Mouse anti-
rat monoclonal anti-prolyl 4-hydroxylase β primary antibody (Millipore, MAB2073MI) 
was used for IF at a dilution of 1:500 in blocking solution. Goat anti-Mouse IgG 
(Invitrogen, 110-33) was used as the secondary antibody. Two wells from each study 
group were allotted for each protein of interest, one well as a positive control with 
primary and secondary antibody steps and one well as a negative control with PBS and 
secondary antibody steps. In order to image the cells stained on the Collagen type I 
coated plates, the bottom of the well was cut out and placed upside-down on the slide. 
Cells cultured for molecular analysis were trypsinized using 0.5mL media for six 
minutes and then neutralized with 3mL media. After cells were dislodged, they were spun 
down and re-suspended in RNAlater in RNase free tubes and tRNA was isolated using 
the protocol above. 
Gene expression was analyzed by quantifying the RNA using the Agilent 
Bioanalyzer Chip, reverse transcribing the tRNA and preforming rt-PCR using the above 
protocols. The genes of interest included Collagen type I, Collagen type III, Scleraxis, 
and Tenomodulin with 18S as the housekeeping gene (as listed in Table 2.1). Isolated 
tenocytes were used as a positive control and undifferentiated stem cells cultured in 
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control media for seven days were used as a negative control for gene analysis. PCR 2-
ΔΔCt values were normalized to the negative control to determine relative expression. 
 
STUDY 2: DETERMINING THE IDEAL DIFFERENTIATION PERIOD: 7 VS 14 
DAYS  
The second study focused on gene expression (n=18 wells) and histological 
expression (n=6 wells) of cells cultured in BMP-12 in static conditions for both seven 
and 14 days on monolayer. A seeding density of 100,000 cells per well in a six-well plate 
was used. Each group was cultured in DMEM/F12 (1g/L glucose) with 2% FBS, 1% 
Ab/Am, 1X ITS, and 50ng/mL BMP-12, as stated in Table 2.4, and the media was 
changed every three days during the study period. Live/Dead histological staining was 
performed on the scaffolds at the end of seven and 14 days to determine the viability of 
the cells according to the protocol above. 
To isolate tRNA for gene expression analysis via rt-PRC, the cells were removed 
from the 6-well plate using trypsin. Trypsin was allowed to sit for 5 minutes at 37°C and 
the neutralized with 10x the volume of control media. Three wells were pooled and three 
scaffolds were pooled within individual study groups for both time periods (n=6 
samples). After isolation, the tRNA was quantified using the Agilent Bioanalyzer Chip, 
the tRNA was reverse transcribed, and rt-PCR was preformed on the cDNA for Collagen 
type I, Collagen type III, Scleraxis, and Tenomodulin with 18S as the housekeeping gene 
(as listed in Table 2.1). All samples were normalized to undifferentiated Lewis rat 
Adipose Derived Stem Cells cultured on monolayer for statistical analysis. All gene work 
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was performed according to the protocols above. Media samples were also collected from 
the wells every three days when the media was changed and stored at -80°C. 
 
STUDY 3: DETERMINING THE IDEAL DIFFERENTIATION SUPPLEMENTATION 
USING GENE ANALYSIS: BMP-12, TGF- Β1, OR A COMBINATION 
The third study focused on the gene expression of cells cultured in static 
conditions for seven days and 14 days on monolayer at passage 4. Cells were seeded in 
six well plates at a density of 100,000 cells per well. Control cells were cultured at each 
time point (n=3, 3, 6 respectively) in control medium with DMEM (1g/L glucose) with 
10% FBS, and 1% Ab/Am, containing no additional supplement. Experimental groups 
were cultured in the same media with 50ng/mL BMP-12 (n= 12 wells), 10ng/mL TGF-β1 
(n=12 wells), or a combination of the two, added as described in Table 2.4. For each 
media at each time point there was an n=6 wells.  
For tRNA isolation at each time point, trypsin was not used to detach the cells 
from the well plate surface. Instead, 350µL RLT buffer was placed into the well and the 
cells were removed with a cell scraper. After isolation, tRNA was quantified using the 
NanoDrop 2000. Gene expression was evaluated for each study group and time point 
using the protocols above. rt-PCR was preformed on the cDNA for Collagen type I, 
Collagen type III, Scleraxis, and Tenomodulin with 18S as the housekeeping gene (as 
listed in Table 2.1). Isolated tenocytes were used as a positive control and 
undifferentiated stem cells cultured in control media for either seven days or 14 days 
were used as a negative control for gene analysis. PCR 2-ΔΔCt values were normalized to 
the negative control at the respective culture period to determine relative expression. 
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STUDY 4: DETERMINING THE IDEAL DIFFERENTIATION SUPPLEMENTATION 
USING PROTEIN ANALYSIS: BMP-12, TGF- Β1, OR A COMBINATION 
The fourth study focused on the protein expression of Lewis rat Adipose Derived 
Stem Cells at passage 5. Cells were cultured in static conditions for seven days (n =18 
wells) and 14 days (n= 18 wells) on monolayer in six well plates. A seeding density of 
100,000 cells per well was used. Control groups were cultured in DMEM (1g/L glucose) 
with 10% FBS, and 1% Ab/Am. The same solutions were used for the two experimental 
groups, in addition to either 50ng/mL BMP-12 or 10ng/mL TGF-β1. Proteins were 
isolated from the wells using RIPA buffer and protein expression for each study group 
was analyzed using the respective protocols above. The proteins of interest included 
Collagen type I, Collagen type III, Scleraxis, and Tenomodulin. The antibodies and the 
dilutions in 0.5% non-fat dried milk that were used are as follows: Anti-Collagen I 
antibody diluted 1:5000 (Abcam, ab34710), Anti-Collagen III antibody diluted 1:5000 
(Abcam, ab7778), Anti-SCXA antibody diluted 1:10,000, 1:1000, and 1:200, (Abcam, 
ab58655), and Tenomodulin diluted 1:200 (Santa Cruz Biotech, Inc., sc-98875). 
Membranes were analyzed using the protocol above. The following densities were used 
to find the protein band: 22kDa for Scleraxis, 37.1kDa for Tenomodulin, 122kDa for type 
I collagen, and 138kDa for type III collagen. Media samples were also collected every 







STUDY 5: DETERMINING THE IDEAL DIFFERENTIATION SURFACE: 
MONOLAYER VS. DECELLULARIZED PORCINE PERICARDIUM 
The fifth study focused on the gene expression of Lewis rat Adipose Derived stem 
cells seeded on 1) decellularized porcine pericardium scaffolds supplied by Mike Jaeggli 
and 2) on monolayer. The scaffolds were cut into 18mm circles using a sterile punch, cut 
into half-moons, and sterilized using the protocol above. Cells were either cultured in 
BMP-12 differentiation media (n-6 wells) or control media (n=6 wells) as described in 
Table 2.4. A seeding density of 1,000,000 cells per scaffold was used. 
tRNA was isolated from the scaffolds using the protocol above. After isolation, 
tRNA quantification was determined using the NanoDrop 2000. Gene expression was 
evaluated for each study group using the reverse transcription and rt-PCR protocols 
above. rt-PCR was preformed on the cDNA for Collagen type I, Collagen type III, 
Tenomodulin, and Scleraxis (rat), with 18-S as the housekeeping gene (listed in Table 
2.1). Isolated tenocytes were used as a positive control and undifferentiated stem cells 
cultured in control media for seven days were used as a negative control for gene 
analysis. PCR 2-ΔΔCt values were normalized to the negative control to determine relative 
expression where possible. There were not enough tenocyte and BMP-12 samples to 
determine standard deviations and therefore statistical differences may not be indicated. 
 
2.4. Results  




Once the Adipose Derived Stem Cells were cultured in their appropriate 
mediums, they were stained to ensure differentiation had occurred. Lewis rat Adipose 
Derived stem cells cultured in CM under micromass conditions were stained for GAGs 
using Alcian Blue (Table 2.3) and as you can see in Figure 2.1, there is GAG content 
present.  
 
Figure 2.1: Histological staining of isolated Lewis rat Adipose Derived Stem Cells that 
have undergone Chondrogenesis. The cells are stained with Alcian Blue for sulfated 
glycosaminoglycan deposition to ensure differentiation. 
 
Cells cultured with AM to induce Adipogenesis were stained with Oil Red-O to 
observe intracellular lipid accumulation. As you can see below in Figure 2.2, the cells did 
exhibit lipid accumulation, although not all the cells stained positively. 
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Figure 2.2: Histological staining of isolated Lewis rat Adipose Derived Stem Cells that 
have undergone Adipogenesis. The cells are stained with Oil Red-O for intracellular lipid 
accumulation to ensure differentiation. 
 
Lastly, LRAD stem cells cultured in OM to induce Osteogenesis stained 
positively, as shown in Figure 2.3, for extracellular calcium deposition.  
 
Figure 2.3: Histological staining of isolated Lewis rat Adipose Derived Stem Cells that 
have undergone Osteogenesis. The cells are stained with Alizarin Red for extracellular 
calcium deposition to ensure differentiation. 
 
 As depicted in the Figures above, the ADSCs isolated from the Lewis rats are 
capable of differentiating down multiple lineages, signifying they are multipotent and 
capable of differentiating into tenocytes. 
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2.4.2. Study 1: Determining the ideal mechanical differentiation condition: 
dynamic loading vs. static 
 
Cells cultured in BMP-12 differentiation media on monolayer for seven days 
fluoresced positively for prolyl-4-hydroxylase, confirming the fibroblast-like nature of 
the cells characteristic of tenocytes. Negative controls not incubated in secondary 





Figure 2.4: Prolyl-4-hydroxylase immunofluorescence staining on cells cultured on 
monolayer for seven days in BMP-12 differentiation media.                                                                                                                                                                                              
 
PCR results have shown that gene expression is higher in the static group cultured 
in BMP-12 for seven days than in the dynamic group for Collagen I, 2.37 and 0.59, 
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respectively. Collagen type I gene expression is also significantly higher for cells 
cultured on static surfaces for seven days, 2.37, than cultured tenocytes, 0.28. PCR has 
also shown that cells cultured statically, 5.12, and dynamically, 3.56, both have an 
increase in type III collagen than cultured tenocytes on monolayer, 0.01. These results 















































































































































Figure 2.5: Relative fold increase or decrease in gene expression of A) Scleraxis, B) 
Tenomodulin, C) Collagen type I, and D) Collagen type III among cells cultured 
statically (red) or dynamically (teal), and cultured tenocytes (grey). A connecting 
horizontal line at the top of the graph represents statistical differences between groups. 
Standard error bars are present. All values were normalized to undifferentiated Adipose 
Derived Stem Cells (n=3). 
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2.4.3. Study 2: Determining the ideal differentiation period: seven vs. 14 days  
 
Cells cultured in BMP-12 differentiation media on monolayer are capable of 
staying alive for a minimum of seven days, as shown in Figure 2.6 below. Live cells 
fluoresce green and dead cells fluoresce red. 
 
 
Figure 2.6: Live/Dead imaging of ADSCs cultured on monolayer in BMP-12 
differentiation media for seven days. 
 
PCR results have shown that gene expression is higher in the group cultured in 
BMP-12 for seven days than in the group cultured for 14 days for type I collagen, 1.29 
and 0.54, respectively. These cells cultured for seven days and 14 days also show an 
increased expression of type I collagen compared to cultured tenocytes, 0.06. However, 
cells cultures for seven days in BMP-12 expressed Scleraxis significantly less than 












































































































































Figure 2.7: Relative fold increase or decrease in gene expression of A) Scleraxis, B) 
Tenomodulin, C) Collagen type I, and D) Collagen type III among cells cultured 
statically for seven (orange) or 14 days (purple), or compared to cultured tenocytes 
(grey). A connecting horizontal line at the top of the graph represents statistical 
differences between groups. Standard error bars are present. All values were normalized 
to undifferentiated Adipose Derived Stem Cells (n=3). 
 
2.4.4. Study 3: Determining the ideal differentiation supplementation using gene 
analysis: BMP-12, TGF- β1, or a combination 
 
PCR has shown that at day 7, BMP-12 evokes a significantly higher expression of 
Scleraxis, 57.81, compared to TGF-β1, 12.54, the combination of BMP-12 and TGF-β1, 
0.85, and tenocytes, 0.01. After 14 days of differentiation, BMP-12 evoked a statistically 
higher expression of Scleraxis, 1.29, than the combination differentiation group, 0.44, or 
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cultured tenocytes, 0.09. TGF-	  β1 also caused the cells to significantly increase the 
expression of Scleraxis, 1.29, compared to tenocytes, as shown in Figure 2.8. When 
comparing expression levels for each treatment from day seven to day 14, we see that 
Scleraxis expression is higher in the group differentiated in BMP-12 for seven days, 
57.81, versus 14 days, 1.29, and ADSCs cultured in the combination of BMP-12 and 
TGF-β1 for seven days, 6.69, versus 14 days, 0.44. 
Tenomodulin expression is significantly decreased in all groups at day 14 
compared to tenocytes, 120.02. There are no statistical differences in Tenomodulin 
expression between the experimental groups cultured for seven days, nor are there any 
statistical differences in Tenomodulin expression levels from day 7 to day 14 within any 
of the experimental groups, as shown in Figure 2.9. 
At seven days, BMP-12 differentiation also evokes a significantly higher 
expression of Collagen I, 3.66, compared to TGF-β1 differentiation, 2.04, to combination 
differentiation using BMP-12 and TGF-β1, 0.85, and to tenocytes, 0.01. Cells 
differentiated for seven days in TGF-β1 also significantly increased expression of 
Collagen type I than tenocytes. At 14 days, TGF-β1 differentiation also elicited a higher 
expression of type I collagen than BMP-12 differentiation, 0.44, combination 
differentiation using BMP-12 and TGF-β1, 0.53, and cultured tenocytes, 0.01.  In 
addition, cells cultured in BMP-12 for seven days expressed Collagen type I significantly 
higher than cells cultured in BMP-12 for 14 days, as shown in Figure 2.10. Lastly, there 
were no significant differences in the expression of type III collagen between any of the 















































































































































Figure 2.8: Relative fold increase or decrease in gene expression of Scleraxis among 
Lewis rat Adipose Derived Stem Cells cultured in BMP-12 or TGF-β1, a combination of 
BMP-12 and TGF-β1, or tenocytes for seven (orange) and 14 days (purple). Statistical 
analysis was performed A) across each group within the same time point or B) within 
each group across the two time points. A connecting horizontal line at the top of the 
graph represents statistical differences between groups. Standard error bars are present. 












































































































































Figure 2.9: Relative fold increase or decrease in gene expression of Tenomodulin among 
Lewis rat Adipose Derived Stem Cells cultured in BMP-12 or TGF-β1, a combination of 
BMP-12 and TGF-β1, or tenocytes for seven (orange) and 14 days (purple). Statistical 
analysis was performed A) across each group within the same time point or B) within 
each group across the two time points. A connecting horizontal line at the top of the 
graph represents statistical differences between groups. Standard error bars are present. 














































































































































Figure 2.10: Relative fold increase or decrease in gene expression of Collagen type I 
among Lewis rat Adipose Derived Stem Cells cultured in BMP-12 or TGF-β1, a 
combination of BMP-12 and TGF-β1, or tenocytes for seven (orange) and 14 days 
(purple). Statistical analysis was performed A) across each group within the same time 
point or B) within each group across the two time points. A connecting horizontal line at 
the top of the graph represents statistical differences between groups. Standard error 
bars are present. All values were normalized to undifferentiated Adipose Derived Stem 



















































































































































Figure 2.11: Relative fold increase or decrease in gene expression of Collagen type III 
among Lewis rat Adipose Derived Stem Cells cultured in BMP-12 or TGF-β1, a 
combination of BMP-12 and TGF-β1, or tenocytes for seven (orange) and 14 days 
(purple). Statistical analysis was performed A) across each group within the same time 
point or B) within each group across the two time points. A connecting horizontal line at 
the top of the graph represents statistical differences between groups. Standard error 
bars are present. All values were normalized to undifferentiated Adipose Derived Stem 
Cells (n=3).  
 
2.4.5. Study 4: Determining the ideal differentiation supplementation using protein 
analysis: BMP-12, TGF- β1, or a combination 
 
Studies revealed that there was no Scleraxis protein expression or type III 
collagen protein expression at either time point. However, cells cultured in BMP-12 for 7 
days exhibited the highest expression of Tenomodulin, followed by BMP-12 culture cells 
at day 14. Cells cultured in TGF-β1 for seven days expressed more Tenomodulin protein 
than at 14 days, however cells cultured in the combination media expressed higher 
amounts of Tenomodulin at day 14 than at day seven. Collagen type I protein expression 
was higher at day seven for cells cultured in BMP-12 differentiation media and TGF-β1 
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differentiation media, however cells cultured in a combination expressed more Collagen 
type I at day 14 than at day seven. Such results can be seen below in Figure 2.12. 
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Figure 2.12: A) Scleraxis. B) Tenomodulin, C) Collagen type I, and D) Collagen type III 
protein expression (Relative Density Unit) of ADSCs differentiated in either BMP-12 
media, TGF-β1 media, or media containing BMP-12 and TGF-β1. The cells were 
cultured for a total of seven days (orange) and 14 days (purple).  
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2.4.6. Study 5: Determining the ideal differentiation surface: monolayer vs. 
decellularized porcine pericardium 
 
Scleraxis expression and type III collagen appears to be higher for cells cultured 
in BMP-12 differentiation media on scaffolds compared to undifferentiated ADSCs 
cultured on scaffolds. However, cultured tenocytes have the highest expression of both 




















































































































































































Figure 2.13: Relative fold increase or decrease in gene expression of A) Scleraxis, B) 
Tenomodulin, C) Collagen type I, and D) Collagen type III for BMP-12 differentiated 
cells cultured on scaffolds (teal) and undifferentiated cells cultured on scaffolds (pink) 
for seven days, or compared to cultured tenocytes (grey). All values were normalized to 
undifferentiated Adipose Derived Stem Cells (n=3). 
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2.5. Discussion  
 
Following along with the findings of Zuk et al., Lewis rat inguinal cells were 
proven to be multipotent adipose derived Mesenchymal stem cells capable of 
differentiation into tenocytes, as shown by the yellow box in Figure 2.14 [6]. However, 
the differentiation media and conditions had to first be optimized. Scott et al. showed that 
differentiation of cells under dynamic conditions for 2 hours a day increased expression 
levels of scleraxis and collagen I, and this was exacerbated by increased strain 
percentages up to 7.5%. Past 7.5% strain, there were no statistical differences in the 
expression of scleraxis or collagen I [9]. However, results from Study 1 follow the results 
of Subramony et al. more succinctly. Their studies showed that at 7 days, there were no 
statistical differences in scleraxis, tenomodulin, or collagen I gene expression levels 
when comparing cells subjected to tensile strain. However, collagen III gene expression 
levels were up-regulated in the group subjected to loading [10]. However, this up-
regulation alone without the up-regulation of collagen I may not be a good thing because 
with injury occurs within a tendon, there tends to be a higher collagen III presence when 
the tendon is healed compared to healthy tendon, reducing the mechanical properties of 
the tendon. Therefore, the cells undergoing loading and expressing high levels of 
collagen III may be a result of the cells being stimulated to think they being damaged, 
and therefore laying down this collagen III. 
In comparison, it was found in Study 1 that Collagen I expression levels were 
significantly up-regulated in the static differentiation group compared to the dynamic 
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differentiation group, and scleraxis appeared to follow the same trend. This could 
potentially be due to the fact that cells were undergoing biaxial loading instead of 
uniaxial loading, which is less similar to physiological conditions within a tendon and 
therefore doesn’t promote differentiation into a tenocyte. It was also noted that none of 
the ADSCs exhibited significant changes in tenomodulin expression compared to 
undifferentiated ADSCs, this is likely due to the fact that tenomodulin is considered a 
late-stage marker for tenocytes. Therefore, we are seeing high levels of expression of 
tenomodulin from the isolated mature tenocytes, but low expression levels from the 
differentiating cells. In conclusion, the static differentiation would prove to the best 





Figure 2.14. Potential Mesenchymal stem cells differentiation lineages. 
 
 Study 2 focused on the ideal differentiation period for inducing tenocyte-like 
expression in the cells. A study done by Park et al. showed decreased expression of both 
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scleraxis and tenomodulin from day 6 to day 12 in cells treated with 100ng/mL GDF-5, 
but an increase in collagen I, therefore leading me to believe that a 7 day differentiation 
period would be ideal [11]. Unfortunately, however tenomodulin expression was down-
regulated in the cells treated with BMP-12 normalized to undifferentiated tenocytes 
cultured for the same duration. However, scleraxis does follow the trend seen by Park, 
with increase expression at 7 days versus 14 days. This is verified by the results from 
Study 3. The expression of all the genes is up-regulated at day 7 compared to day 14 
when treated with BMP-12.  In addition, tenocyte expression for each of the markers is 
fairly low, however this does not mean these markers are not a good indicator of 
tenocytes. It is believed that expression levels for tenocytes was decreased due to the fact 
that the cells were directly isolated from mature tendons and the RNA was isolated 
immediately. Therefore, because the cells were not cultured like the experimental groups, 
they never needed to establish a comparable new extracellular matrix or tenocyte like 
environment, potentially making their expression levels lower. This same trend is seen 
throughout each of the studies for both AIM 1 and AIM 2. For Study 3, I also wanted to 
observe the differentiation effects of TGF-β1. Originally I hypothesized that expression 
of the tenocyte markers would be elevated in the group treated with the combination 
media, however after the study was completed it was learned that BMP-12 is part of the 
TGF-β superfamily, and therefore instead of working together to further induce tenogenic 
differentitaion in the cells, it is highly possible they had more of a competitive 
relationship, and therefore expression for each of the markers was decreased. In addition, 
BMP-12 induced a higher expression profile of the tenocyte markers, scleraxis, collagen 
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I, and collagen III compared to TGF-β1. Studies have found that reduction in TGF-β at 
injury sites is assocaited to a decrease in scar formation [12]. Therefore, when TGF-β is 
present, it could be promoting more “scar formation” than tenocyte differentation, 
causing expression levels to be reduced.  
Study 4 was performed to determine whether there was link in gene expression 
levels and the presence of protein expression in each of the experimental groups. 
Unfortunately, no protein expression was seen for collagen III or scleraxis. Due to the 
fact that scleraxis is a transcription factor and only present in a cell for a very short period 
of time, it was believed this was why no expression was seen (because the western blot 
was carried out at multiple antibody concentration and nothing was seen for any of them). 
However, there is a possibility that the antibodies were not binding appropriately, which 
is why I believe we see no expression of collagen III.  
When comparing Study 3 data to Study 4 data, we see that there was a large 
expression of collagen I gene at 7 days and hardly any expression at 14 days, however 
this is not represented in the protein analysis. Protein expression levels at day 14 are 
approximately half of the amount of expression seen at day 7. However tenomodulin 
expression levels do seem to follow the same trend from gene expression to protein 
expression within the BMP-12 differentiation group and the TGF-β1 differentaion group. 
However, the combination group which shower higher gene expression at day 7 showed 
higher protein expression of tenomodulin at 14. This is also the case for collagen I 
expression levels in seen from the combination group.  Therefore, BMP-12 and TGF-β1 
showed the higher reproducibility from gene expression to protein expression, further 
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verifying that these groups are more capable of inducing a tenocyte-like phenotype in the 
adipose derived stem cells. Furthermore, BMP-12 seems to do this more than TGF-β1. 
Lastly, the cells ability to differentiate on a scaffold was analyzed. Scleraxis, 
collagen I, tenomodulin, and collagen III gene expression levels were all downregulated 
when normalized to undifferentiated adipose derived stem cells cultured on monolayer. 
Because previous studies showed us that differentiation on monolayer using BMP-12 
induces higher expression of these genes, we can then conclude that differentiation on a 
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AIM 2: EVALUATION OF THE INTRODUCTION OF DIFFERENTIATED LEWIS 
RAT ADIPOSE DERIVED STEM CELLS INTO AN INDUCED INJURY SITE IN 
LEWIS RAT ACHILLES TENDON 
3. AIM 2: 
3.1. Introduction 
 
 Due to high re-tear rates seen in tendons and how debilitating these tears can be, 
it is essential to find a method to reduce the number of re-tears. Therefore, AIM 2 focuses 
on effects caused by the introduction of BMP-12 differentiated stem cells into a tendon 




Conexa™ 200 Reconstructive Tissue Matrix (BCP 051020) was purchased from Tornier, 
US. LIVE/DEAD® Viability/Cytotoxicity Assay Kit (L-3224) was purchased from 
Invitrogen. ElectroForce® 3200 Series II and load cell was purchased from Bose. 
Weigert’s Hematoxylin Solution (A&B set) (S216B) and Masson’s Trichrome Method 
for Connective Tissue (K037) were purchased from Polyscientific. Recombinant Mouse 
GDF-7/BMP-12 (779-G7) was purchased from R&D Systems. DMEM containing 1g/L 
glucose (MT-10-014-CM), 1X Phosphate Buffered Saline without Ca2+ and Mg+ (MT-
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20-031-CV), BSA from Rockland – fraction V (NC9418785) and Antibiotic/Antimycotic 
(MT-30-004-Cl) were purchased from Fisher Scientific. 
 
3.3. Methods 
3.3.1. Scaffold characterization 
 
For implantation, porcine dermis Conexa™ 200 Reconstructive Tissue Matrix 
(Tornier US, BCP 051020) was chosen as the surface for cell seeding and for 
implantation in the Lewis rats. Because Conexa™ is a sterile medical device, no 
additional sterilization procedures were required. Conexa™ also provides an intact 
extracellular matrix with glycoproteins for cells to bind to and a vascular channels 
allowing for blood perfusion to the host tissue. Each scaffold was cut into 2mmx6mm 
rectangles using a punch specifically manufactured for the project. 
 
3.3.2. Adipose derived stem cell differentiation and scaffold seeding 
 
 
Due to the study results from AIM 1, Lewis rat Adipose Derived Stem Cells were 
seeded into T150’s and cultured with either BMP-12 differentiation media or control 
media, as described in Table 3.1. Cells were allowed to differentiate on monolayer for six 
days and were then trypsinized for cell counting. Due to a high cell confluence, cells 
were re-suspended in collagenase after trypsinization and placed in the incubator at 37°C 
for 45-60 minutes. After, the collagenase was neutralized using control media at 3x the 
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volume of collagenase solution and the cells were spun down and re-suspended in the 
appropriate amount of media to provide 1,000,000 cells per 9uL. Because each scaffold 
was seeded with 1,000,000 of their respective cell types, 9uL was the ideal volume 
because it ensured that all 1,000,000 cells were seeded and adhered to only the top of 
each scaffold for two hours before additional differentiation or control media was added 
for the remaining 72 hours of culturing. A total of 30 scaffold were seeded from each 
study group: scaffold + undifferentiated stem cells and scaffold + BMP-12 differentiated 
stem cells. After the differentiation period was completed, the samples were incorporated 
into the Achilles tendon of rat. 
 
 
3.3.3. Pre-implanted scaffold processing and histological analyses 
 
CELL VIABILITY: LIVE/DEAD IMAGING 
Live/Dead imaging was preformed on two scaffolds from each experimental 
group (seeded with either undifferentiated ADSCs or BMP-12 differentiated ADSCs) 
seeded for three days to ensure the cells were viable before implantation. This was 
performed using the same protocol from AIM 1. 
Table 3.1: Lewis Rat Adipose Derived Stem Cell Media for In-Vivo Study 
     
Study Group Basal Medium* Serum Supplementation 
     
In-vivo 
Control DMEM 10% FBS 1% antibiotic/antimycotic 
BMP-12 
 
DMEM 10% FBS 1% antibiotic/antimycotic 
50ng/mL BMP-12 




Two control Conexa™ scaffolds and two scaffolds from each experimental group 
(seeded with either undifferentiated ADSCs or BMP-12 differentiated ADSCs) seeded for 
three days were placed into 10% formalin for a minimum of 24 hours. The total volume 
of formalin was at least four times the volume of the tissue to ensure thorough fixation. 
They were then labeled according to the Accession log protocol and placed into cassettes 
to be processed in the tissue processor using the protocol below. The total time to 
complete tissue processing is 8 hours. 
 
1. Place samples within their cassettes into the tissue-processing basket. 
2. Run Program 1: step shown in Table 3.2 below. 











Table 3.2: Tissue Processing Procedure 
   
Step Immersion Solution Duration (min) 
   
1 10% Buffered Formalin 30 
2 10% Buffered Formalin 30 
3 70% Ethanol 30 
4 80% Ethanol 30 
5 95% Ethanol 45 
6 95% Ethanol 45 
7 100% Ethanol 45 
8 100% Ethanol 45 
9 Xylene 20 
10 Xylene 40 
11 Paraffin 30 
12 Paraffin 30 
13 Paraffin 30 
14 Paraffin 30 
 
SCAFFOLD EMBEDDING AND SECTIONING 
Processed scaffolds were embedded such that the scaffold was oriented with the 
seeded side face down to obtain longitudinally 5µm sections.  This was done by placing 
the metal embedding tray on the hot plate and filling it with paraffin. Next, the tissue was 
positioned on the bottom of the metal tray in the preferred orientation using tweezers. 
While holding the tissue down, the metal tray was placed onto the cold plate briefly to 
prevent the sample from moving. Then, the cassette was placed on the metal tray and the 
remaining space on top of the cassette was filled with paraffin. The metal tray was then 
immediately moved to the cold plate, allowing the paraffin to harden.  After hardening, 




Prior to sectioning, the water bath was heated to 40°C and coins were placed in 
the bottom to capture the air bubbles floating in the water to prevent interference with the 
sections. Also, the blade was replaced to ensure the sections were cut finely. After 
sending the microtome’s block holder “HOME”, the block was inserted and the blade 
was placed for cutting. Initially, the blocks were trimmed at 15 microns to reach the 
samples within the wax, and once the appropriate depth was achieved, sections were 
taken at 5 microns. After sectioning, the slides were placed in the oven overnight to 




HEMATOXYLIN AND EOSIN (H&E) 
Processed Conexa™ scaffolds were stained with Weigert’s Hematoxylin 
Solution, A&B set (Polyscientific, S216B) using the protocol below in Table 3.3. Richard 
Bruner of Research Pathology Associate, LLC compared stained pre-implanted scaffolds 
to H&E stained implanted scaffolds according to the protocol in the following section. 
From the Hematoxylin and Eosin, the nuclei were stained blue, the erythrocytes and 
eosinophilic granules were stained bright pink to red, and the cytoplasm and other tissue 




Table 3.3: Hematoxylin and Eosin Staining Procedure  
   
Step Immersion Solution Duration 
   
1 Xylenes 10 dips 
2 Xylenes 5 min 
3 100% Ethanol 10 dips 
4 100% Ethanol 1 min 
5 95% Ethanol 10 dips 
6 95% Ethanol 1 min 
7 Tap water Till “sheeting” action occurs 
8 Distilled water 1 min 
9 Hematoxylin 5 min 
10 Tap water Till clear 
11 Clarifier 4 dips 
12 Tap water Till “sheeting” action occurs 
13 Bluing reagent 1 min 
14 Tap water 1 min 
15 95% Ethanol 10 dips 
16 Eosin 45 sec 
17 95% Ethanol 10 dips 
18 95% Ethanol 10 dips 
19 100% Ethanol 10 dips 
20 100% Ethanol 1 min 
21 100% Ethanol 3 min 
22 Xylenes 10 dips 






Processed Conexa™ scaffolds were stained using the Masson’s Trichrome 
Methods for Connective Tissue (PolyScientific R&D Corp., k037). Richard Bruner of 
Research Pathology Associate, LLC compared stained pre-implanted scaffolds to 
Masson’s Trichrome stained implanted scaffolds according to the protocol in the 
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following section. Collagen was represented with blue stain and keratin and muscle was 
represented with red stain. 
 
3.3.4. Animal Model 
 
In-vivo surgeries were performed on male Lewis rat Achilles tendons by Richard 
Hawkins M.D., Greg Colbath, M.D., and Theodore Schlegel M.D. Each rat was placed 
into one of three study groups: Conexa™ scaffold containing no cells, Conexa™ scaffold 
containing undifferentiated stem cells, and Conexa™ scaffold containing BMP-12 
differentiated stem cells. Cells were seeded onto the scaffolds using the protocols from 
AIM 1. Each rat (n=60) underwent an intentional window injury, as shown below in 
Figure 3.1, on the right leg while the left leg, or contralateral leg, was left intact and used 
as a control. After an injury was made, the window was bridged by a Conexa™ tendon 
scaffold and sutured into place using non-degradable sutures to ensure durability. The 
implanted scaffold type was chosen based on the study group in which the rat resided. 
These scaffolds remained implanted for a total of seven weeks before Greg Colbath, 




Figure 3.1: Model of the window transection in the Achilles tendon of Lewis rats. The 
transected region was discarded and the Conexa scaffold was sutured into its original 
place. 
 
3.3.5. Implanted Scaffolds 
 
HISTOLOGICAL ANALYSIS 
Four rats from each study group were sacrificed for histological analysis. The 
repaired tendon containing the scaffold and healthy tendon from the contralateral leg of 
each rat were removed. The boney insertion was removed completely from the tendon 
while a small portion of muscle belly was left intact on the opposite end. For each rat, the 
healthy and repaired tendons were labeled and stored separately in formalin filled 
containers for a minimum of 48 hours. The total volume of formalin was at least four 




Before processing the tendon, the muscle belly was removed and the tendon was 
marked with tattoo ink to maintain orientation. 
 
TISSUE PROCESSING PROTOCOL FOR RAT ACHILLES TENDON 
All samples were entered into the Accession log prior to processing. Once each 
sample was placed into a respectively labeled cassette matching the Accession log, they 
were processed using the protocol previously mentioned. 
 
HEMATOXYLIN AND EOSIN STAINING 
Processed control and experimental implanted Conexa™ scaffolds were stained 
using the protocol above. Richard Bruner of Research Pathology Associate, LLC 
compared stained pre-implanted scaffolds to H&E stained implanted scaffolds according 
to the protocol in the following section. From the Hematoxylin and Eosin, the nuclei were 
stained blue, the erythrocytes and eosinophilic granules were stained bright pink to red, 
and the cytoplasm and other tissue elements were stained various shades of pink. 
 
MASSON’S TRICHROME STAINING 
Processed control and experimental implanted Conexa™ scaffolds were stained 
using the same protocol as used for pre-implanted scaffolds. Richard Bruner of Research 
Pathology Associate, LLC compared stained pre-implanted scaffolds to Masson’s 
Trichrome stained implanted scaffolds according to the protocol in the following section. 
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Richard Bruner, an ACVP board-certified pathologist, of Research Pathology 
Associate, LLC performed a histopathologic examination of 1) pre-implanted scaffolds, 
2) healthy control tendons, 3) each of the three groups containing an implanted scaffold. 
Samples were observed microscopically for 1) Findings along the scaffold surface, 2) 
Findings within the central matrix of the scaffold, and 3) Findings associated with the 
juxtaposed native Achilles tendon. Responses were grading as follows: 0 = within normal 
limits, 1 = minimal, 2 = mild, 3 = minimal, 4 = marked (severe).  
 
GENE ANALYSIS 
Six rats from each study group were sacrificed for gene analysis. The repaired 
tendon containing the scaffold and healthy tendon from the contralateral leg of each rat 
were removed. For each rat, the healthy and repaired tendons were separated and labeled 
appropriately until pooling occurred as described later. tRNA was isolated from the 
tendons and analyzed using the protocols from AIM 1. Three tRNA samples were pooled 
from three legs within the same group during isolation to obtain an n=2 samples for both 
healthy and repaired tRNA. After rt-PCR was performed, the samples were normalized to 





Ten rats from each study group were sacrificed for mechanical analysis. Each leg 
was removed and cleaned of excess soft tissue, however leaving a portion of the proximal 
muscle belly and a portion of the calcaneus bone to aid in testing. The leg containing the 
Conexa™ repaired tendon and the healthy, contralateral leg of each rat were removed, 
wrapped separately in PBS soaked gauze and aluminum foil, and frozen at -20°C until 
testing took place. 24 hours prior to testing, the samples were moved to +4°C to allow 
thawing. A total of 46 legs were dissected for testing: 16 control legs and 10 legs from 
each implantation group. Mechanical testing was performed on the ElectroForce® 3200 
Series II with a 100lbf load cell (Bose). Prior to inserting the samples into the Bose, the 
width and thickness of the samples were measured four times and averaged to determine 
to initial cross-sectional area. Samples were placed vertically into the clamps in such a 
way to ensure only the tendon was being mechanically tested. Tendon orientation can be 
seen below in Figure 3.2. For tensile testing, a 2N preload was then applied and the L0 
was measured in mm. All measurements were made with a slide caliper. The tendon was 
then loaded at a rate of 10mm/min and the location of failure was noted. [1] The 
structural properties of the tendon and tendon-scaffold complex were then calculated. 
This included linear stiffness, yield, or ultimate deformation, ultimate load, failure stress, 
and failure strain. Linear stiffness was measured by taking the slope of the Force (N) vs. 
displacement (m) graph from initial load to failure. This was done for each sample and 
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averaged. The mechanical properties of different treatment groups were compared using 
the Student t test and the level of significance was set at p < 0.05. [1] 
 
 
Figure 3.2: Bose mechanical testing setup used to test the load to failure in rat Achilles 




Clamps were designed to grip the tissue firmly, preventing slipping during testing, 
without the use of dry ice. Clemson Machining and Technical Services manufactured the 




Figure 3.3: Tissue Clamps designed for mechanical testing.  
 
3.4. Results 
3.4.1. Seeding viability on scaffolds 
 
Scaffolds seeded with undifferentiated Adipose Derived Stem Cells or BMP-12 
differentiated cells were stained with a LIVE/DEAD® Viability/Cytotoxicity Assay Kit in 
order to determine cell viability before implantation. Representative images were taken 
and shown in Figure 3.4 below. No dead cells were observed, however the scaffold does 








Figure 3.4: Cell viability of A) Undifferentiated ADSCs seeded onto Conexa scaffold or 
B) BMP-12 differentiated ADSCs seeded onto Conexa for a total of 72 hours after being 
cultured on monolayer. Live cells are depicted in green and dead cells are depicted in 
red.  
 
3.4.2. Histological analysis 
 
HEMATOXYLIN AND EOSIN 
Pre-implanted scaffolds seeded with undifferentiated Adipose Derived Stem Cells 
(A) or BMP-12 differentiated cells (B) were stained with Hematoxylin and Eosin (H&E), 
as seen in Figure 3.5. Similar scaffolds implanted into the Achilles tendon were removed 
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after seven weeks and were also stained with H&E. The study groups include A) healthy, 
non-injured tendon, B) tendon mended with an unseeded Conexa scaffold, C) tendon 
mended with an undifferentiated ADSC seeded Conexa scaffold, and D) tendon mended 
with a BMP-12 differentiated ADSC seeded Conexa scaffold. These images can be seen 
below in Figure 3.6. 
 
 
Figure 3.5: Hematoxylin and Eosin staining of pre-implanted Conexa scaffolds seeded 
with A) Undifferentiated ADSCs or B) BMP-12 differentiated for a total of 72 hours after 
being cultured on monolayer. The extracellular matrix is represented with pink stain and 




















Figure 3.6: Hematoxylin and Eosin staining of A) healthy control tendons, or repaired 
tendon containing a Conexa scaffold seeded with B) No cells, C) Undifferentiated ADSCs 
or D) BMP-12 differentiated ADSCs. Scaffolds were implanted for a total of seven weeks. 
The extracellular matrix is represented with pink stain and the cell nuclei are represented 
with purple stain. 
 
MASSON’S TRICHROME 
Pre-implanted scaffolds seeded with A) no cells, B) undifferentiated Adipose 
Derived Stem Cells, or C) BMP-12 differentiated cells were stained with Masson’s 
Trichrome (MT), as seen in Figure 3.7. Similar scaffolds implanted into the Achilles 
tendon were removed after seven weeks and were also stained with MT. The study 
groups include A) healthy, non-injured tendon, B) tendon mended with an unseeded 
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Conexa scaffold, C) tendon mended with an undifferentiated ADSC seeded Conexa 
scaffold, and D) tendon mended with a BMP-12 differentiated ADSC seeded Conexa 
scaffold. These images can be seen below in Figure 3.8. 
 
 
Figure 3.7: Masson’s Trichrome staining of pre-implanted Conexa scaffolds seeded with 
A) No cells, B) Undifferentiated ADSCs, or C) BMP-12 differentiated for a total of 72 
hours after being cultured on monolayer. Collagen is represented with blue stain and 

















Figure 3.8: Masson’s Trichrome staining of A) healthy control tendons, repaired tendon 
containing a Conexa scaffolds seeded with B) No cells, C) Undifferentiated ADSCs or D) 
BMP-12 differentiated ADSCs. Scaffolds were implanted for a total of seven weeks. 




 Samples underwent a histopathologic evaluation and were scored according to the 
above protocol. Samples scores can be found below. Pre-implanted scaffold scores can be 
found in Table 3.4. Samples taken from the control, healthy legs of rats after the duration 
of the animal study can be found below in Table 3.5. Scores evaluating the implanted 
scaffolds containing no cells, undifferentiated ADSCs, or BMP-12 differentiated ADSCs 





Table 3.4: Histopathologic Examination Scores: Pre-implanted Scaffolds 
    







    
Scaffold Surface (n=2)    
Undifferentiated cells 0,0 2,0 0,0 
Spindle Cells 0,0 1,0 0,1 
Macrophages 0,0 0,0 0,0 
Lymphocytes 0,0 0,0 0,0 
Plasma cells 0,0 0,0 0,0 
Neutrophils 0,0 0,0 0,0 
Adipose cells 0,0 0,0 0,0 
Neovascularity 0,0 0,0 0,0 
    
Scaffold Matrix (n=2)    
Undifferentiated cells 0,0 0,0 0,0 
Spindle Cells 0,0 0,0 0,1 
Macrophages 0,0 0,0 0,0 
Lymphocytes 0,0 0,0 0,0 
Plasma cells 0,0 0,0 0,0 
Neutrophils 0,0 0,0 0,0 
Adipose cells 0,0 0,0 0,0 
Neovascularity 0,0 0,0 0,0 
 
 
Table 3.5: Histopathologic Examination Scores: Control Tendon  
      
Evaluation Region # of 0s # of 1s # of 2s # of 3s # of 4s 
      
Juxtaposed Tendon (n=11)      
Chondro-osseous   metaplasia 9 2    
Undifferentiated cells 11     
Fibrosis/Fibroplasia 11     
Adipose cells  1 10   







Table 3.6: Histopathologic Examination Scores: Unseeded Scaffold Implants  
      
Evaluation Region # of 0s # of 1s # of 2s # of 3s # of 4s 
      
Scaffold Surface (n=2)      
Undifferentiated cells    2  
Spindle Cells    2  
Macrophages      
Lymphocytes   2   
Plasma cells 2     
Neutrophils 2     
Adipose cells 2     
Neovascularity 2     
      
Scaffold Matrix (n=2)      
Undifferentiated cells  1 1   
Spindle Cells   1 1  
Macrophages 2     
Lymphocytes 1 1    
Plasma cells 2     
Neutrophils 2     
Adipose cells 2     
Neovascularity 2     
      
Juxtaposed Tendon (n=4)      
Chondro-osseous metaplasia 1 1  1 1 
Undifferentiated cells 1  3   
Fibrosis/Fibroplasia 1  3   
Adipose cells 3 1    













Table 3.7: Histopathologic Examination Scores: Undifferentiated ADSC 
Seeded Scaffold Implants  
      
Evaluation Region # of 0s # of 1s # of 2s # of 3s # of 4s 
      
Scaffold Surface (n=2)      
Undifferentiated cells    1 1 
Spindle Cells   1 1  
Macrophages      
Lymphocytes  2    
Plasma cells 2     
Neutrophils 2     
Adipose cells 2     
Neovascularity 1 1    
      
Scaffold Matrix (n=2)      
Undifferentiated cells  1 1   
Spindle Cells   2   
Macrophages 2     
Lymphocytes 2     
Plasma cells 2     
Neutrophils 2     
Adipose cells 2     
Neovascularity 2     
      
Juxtaposed Tendon (n=3)      
Chondro-osseous   metaplasia 1 1 1   
Undifferentiated cells 2  1   
Fibrosis/Fibroplasia 1 1 1   
Adipose cells 2 1    












Table 3.8: Histopathologic Examination Scores: BMP-12 Differentiated 
ADSC Seeded Scaffold Implants  
      
Evaluation Region # of 0s # of 1s # of 2s # of 3s # of 4s 
      
Scaffold Surface (n=4)      
Undifferentiated cells   4   
Spindle Cells  1 3   
Macrophages      
Lymphocytes 1 2 1   
Plasma cells 4     
Neutrophils 4     
Adipose cells 4     
Neovascularity 3 1    
      
Scaffold Matrix (n=4)      
Undifferentiated cells 2 1 1   
Spindle Cells  2 2   
Macrophages 4     
Lymphocytes 3  1   
Plasma cells 4     
Neutrophils 4     
Adipose cells 4     
Neovascularity 3 1    
      
Juxtaposed Tendon (n=4)      
Chondro-osseous   metaplasia  2 1  1 
Undifferentiated cells 3    1 
Fibrosis/Fibroplasia   4   
Adipose cells 4     
Neovascularity 2 1 1   
 
Results showed that implant groups (scaffold only, scaffold seeded with 
undifferentiated stem cells, and scaffold seeded with BMP-12 differentiated stem cells) 
were very similar. Overall, there was a high presence of mononuclear cells with pale 
staining cytoplasm. This is a characteristic prevalent in differentiating stem cells, 
macrophages, and even possibly fibroblasts or synovial cells. In terms of the scaffold 
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implantation groups, there was a population of spindle cells that aligned along the 
collagen bundles within the scaffold and along the surface, which can be seen below in 
A) of Figure 3.9. These cells possessed dark staining and according to the histopathologic 
report, these cells have the potential to differentiate into mature fibrocytes or tenocytes. 
Despite their presence, however, there was no distinct fibrous capsule surrounding the 
scaffold. This is promising because the presence of a fibrous capsule is typically a feature 
seen around implants undergoing host rejection. In addition, there was a general absence 
of plasma cells, which are found in regions with antigenic presence. Although this is the 
case, there was still a high prevalence of inflammatory cells indicating the scaffold may 
have been acting as a foreign body irritant. This can be seen below in B) of Figure 3.9. It 
is possible the scaffold was jagged and therefore irritating the surrounding regions. In 
addition, the cells may have been present due to the surgical damage that occurred to the 
native Achilles tendon. Interestingly, where the image is labeled *, you can see that the 
scaffold has either fully integrate with the tendon in this region, or the cells have 
remodeled the scaffold into a tendon-like composition. Lastly, in the rats that underwent 
scaffold implantation, there was a prevalence of chondro-osseous metaplasia in the native 
surrounding tendon, as seen in C) of Figure 3.9. This was characterized by the presence 
of chondrocytes undergoing mineral deposition within the tendon. However, this focal 









Figure 3.9: Hematoxylin and Eosin staining of A) cells infiltrating the scaffold matrix of 
tendon implanted with a scaffold seeded in undifferentiated ADSCs, B) an inflammatory 
response around an implanted scaffold containing BMP-12 differentiated ADSCs, and C) 
chondro-osseous metaplasia occurring within the tendon implanted with a scaffold 
containing no seeded cells. 
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3.4.3. Gene Analysis 
 
Healthy tendons and tendons containing implanted scaffolds were removed from 
the three experimental groups of the animal study. In conjunction with these groups, 
RNA was isolated and quantified from pre-implanted scaffolds seeded with either 
undifferentiated ADSCs or BMP-12 differentiated ADSCs. These values were 
normalized to pre-implanted scaffolds seeded with undifferentiated ADSCs. As the 
graphs show in Figure 3.10, scleraxis expression is statistically reduced in each of the 
experimental groups compared to healthy tendon, however there are no statistical 
differences in expression levels between the experimental groups.  To note, implanted 
scaffolds containing BMP-12 differentiated ADSCs are the only group whose scleraxis 
expression levels were not significantly reduced compared to the healthy tendon. 
Tenomodulin expression was statistically higher in the group containing a 
scaffold seeded with undifferentiated ADSCs compared to healthy tendons. This group 
and the group containing a scaffold seeded with BMP-12 differentiated cells also express 
tenomodulin significantly higher than pre-implanted scaffolds containing BMP-12 
differentiated cells. The implant groups containing either undifferentiated stem cells, 
BMP-12 differentiated ADSCs, or no cells also express collagen I significantly higher 
pre-implanted scaffolds containing BMP-12 differentiated ADSCs. However, implants 























































































































































































































Figure 3.10: Pre-implanted scaffolds, implanted scaffolds, and healthy tendon expression 
levels of A) Scleraxis, B) Tenomodulin, C) Collagen I, and D) Collagen III normalized to 
pre-implanted scaffolds seeded with undifferentiated ADSCs (n=3). Standard error bars 
are present. Connecting horizontal bars represent statistical differences (p<0.05).  
 
3.4.4. Mechanical Analysis 
 
The average ultimate load, the ultimate load range, the average ultimate 
deformation, the average failure stress, the average failure strain, and the average 
stiffness were calculated for each experimental group and are shown in Table 3.9 below. 
With respect to the average ultimate load, there was no statistical difference between any 
of the four groups. Similarly, there was no statistical difference between any two groups 
with respect to average ultimate deformation. There was a statistical difference in the 
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failure stress between the control group and the three remaining experimental groups: 
scaffold only (p<0.0001), scaffold seeded with undifferentiated ADSCs (p<0.0001), and 
scaffold seeded with BMP-12 differentiated ADSCs (p<0.0001). However, there were no 
statistical differences between these three groups. Finally, there was statistical difference 
in the average failure strain between the control group and the group implanted with 
scaffolds seeded with undifferentiated ADSCs (p=0.0489) and between the control group 
and the group implanted with scaffold seeded with BMP-12 differentiated ADSCs 
(p=0.0439). There were no statistical differences between the group implanted with 
unseeded scaffolds and the other three experimental groups. 
 
Table 3.9: Mechanical testing results  


















































Mechanical data showed that there were no statistical differences between the 
average failure stresses of the three experimental groups, however the control tendon was 
stronger. Unfortunately, this means the scaffold is either masking the effects of the cells 
due to its composition, or the cells are having no effect on the tendon healing. In addition, 
the control tendons were capable of elongating a further distance before failure than the 
groups containing the scaffolds with seeded cells. However, there are again no 
differences between the experimental group implying the scaffolds either masked the 
effects of the cells of the cells had no effect. 
 Gene analysis showed similar results in that healthy tendons expressed higher 
levels of scleraxis mRNA transcript than the experimental groups, but there we no 
differences between the experimental groups. However, collagen III, tenomodulin, and 
collagen I expression was up-regulated in the group containing scaffolds seeded with 
undifferentiated adipose derived stem cells compared to the healthy tendon. This could be 
due to the immune suppressing effects caused by undifferentiated adipose derived stem 
cells. Because the stem cells are slightly suppressing the immune response caused by 
scaffold, it allows us to see the effects of the native cells trying to heal the region by 
secreting collagen I, III, and tenomodulin. Overall however, it is hard to differentiate the 
effect of the implanted cells due to the presence of the matrix and the fact that native 
tendon was also taken out of the rat with the scaffolds and analyzed, which may be 
masking the results of the cells. 
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Based on the Live/Dead analysis performed on pre-implanted scaffolds, we see 
that the cells are alive and covering the surface of the scaffold. However, from H&E and 
MT histology, this is not prevalent. One reason this may be the case is because the 
scaffold was so dense, the cells did not have enough time to migrate into the scaffold 
prior to implantation. Therefore, when sections were taken, all the cells were on the top 
surface and may have gotten removed from the block during trimming.  From the H&E 
we also see that there is a large population of inflammatory cells surrounding the 
scaffolds, including in the group implanted with a scaffold and no cells. In addition, no 
foreign body giant cells or plasma cells are surrounding the scaffolds in any of the 
groups, leading me to believe that the scaffolds are acting as an irritant instead of an 
antigen. These cells could also be present due to the cytokines released from the tissue 
damaged from the transection. Despite why the cells are present, it is important to note 
that the density of inflammatory cells within each implantation group remains consistent 
and you do not see a reduced immune response in the group implanted with a scaffold 
seeded with undifferentiated stem cells. However, is it important to note that implantation 
of scaffolds seeded with BMP-12 differentiated cells appears to be either fully integrating 
into the tendon, as depicted by the * in Figure 3.9, or the infiltrating cells have remodeled 








1) Grumet RC, Hadley S, Diltz MV, Lee TQ, Gupta R. (2009) Development of a 
new model for rotator cuff pathology: the rabbit subscapular is muscle. 






CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK 
 
AIM 1: Studies have shown that differentiation of adipose derived stem cells isolated 
from the inguinal fat pads of Lewis rats are multipotent and capable of differentiating into 
tenocytes. Studies showed that cells cultured on monolayer for a total of 7 days in BMP-
12 differentiation media induced the most tenocyte-like phenotype in the cells. 
 
 However, in order to more accurately say this, gene studies should be reanalyzed 
compared to tRNA isolated from tenocytes that underwent cells culture, instead of tRNA 
that was directly isolated from extracted tendon. This would be a more similar 
comparison between the tenocytes and cell differentiated for 7 or 14 days because each 
cell type would have to produce an extracellular matrix, which may have increased 
expression for each of our markers in our tenocyte group. However, this would not have 
changed the trends seen between the experimental groups considering all expression 
levels were normalized to undifferentiated ADSCs cultured for the same duration of time 
as the cells undergoing differentiation. 
 Secondly, a differentiation study should be performed comparing cells seeded on 
monolayer and cells seeded on the selected implantation scaffold type. Due to the fact 
that the scaffold type was changed from decellularized porcine pericardium after AIM 1 
was completed, we do not know whether the cells were able to undergo differentiation 
upon the Conexa scaffold, despite its similar composition. 
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AIM 2: Studies have shown that the effect of the implanted cells is masked 
mechanically, molecularly, and histologically by the presence of the Conexa graft. 
However, integration of the graft or remodeling of the graft to resemble tendon is seen in 
the group containing implants seeded with BMP-12 undifferentiated stem cells.  
 
For future studies, a graft that is capable of being fully remodeled by cells by the 
end of the study period is necessary to see the full effects of the stem cells. One 
possibility would be decellularized porcine pericardium. Another option would be to use 
fibrin as a cell carrier because it would be completely dissolved by the end of the study 
period and would allow us to analyze only the effects of the stem cells.  Secondly, the 
animal model for the next study should be larger, and the seeding of the scaffold and its 
insertion should be performed differently. To be able to fully understand the histological 
analysis, it would be beneficial to perform cell tracking on the implanted cells to see 
where they end up, if they’re still alive, if they have continued to differentiate, or if 
they’re proliferating.  
In addition, during mechanical testing, because there was only a window 
transection performed versus a full transection of the tendon at the time of surgery, it was 
impossible to determine whether the mechanical data was measuring the strength of the 
tendon due to the implanted cells/scaffold or the strength of the surrounding healthy 
tendon that was fully intact from insertion to origin. For this study, the tendon and 
scaffold worked as a composite, masking the effects of the stem cells. Next time, a full 
transection should be performed to determine the sole effects of the stem cells. 
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Furthermore, when samples are taken for molecular analysis, it is critical that the scaffold 
be excised from the surrounding tendon as much as possible to ensure the native tendon 
isn’t masking the molecular expression of the cells embedded in the scaffold. 
However, studies to be done in the short-term would include 
Immunohistochemistry of the histological sections for macrophages, tenomodulin, 
collagen III, and scleraxis to determine its presence in the scaffold. Performing IHC for 
macrophages will allow is to characterize the inflammatory response and the three other 
markers may allow us to determine any differences between the three implanted groups. 
